Inicio
Producción Científica
1906 resultado(s)
Refinar búsqueda
Refinar búsqueda
Síntomas depresivos, ansiosos e insomnio, y posibles factores asociados en personal de salud, en un Hospital General en Suramérica, durante la pandemia por COVID-19 en 2020 / Camila Valencia Arbeláez ; Carolina Bernal Arbeláez ; Diana Mercedes Ramírez Jiménez ; John Jairo Zuleta Tobón ; Carlos Enrique Yepes Delgado
Título : Síntomas depresivos, ansiosos e insomnio, y posibles factores asociados en personal de salud, en un Hospital General en Suramérica, durante la pandemia por COVID-19 en 2020 Otros títulos : Depressive and anxious symptoms and insomnia, and possible associated factors in health workers, in a General Hospital in South America, during the COVID-19 pandemic in 2020 Tipo de documento : documento electrónico Autores : Camila Valencia Arbeláez, ; Carolina Bernal Arbeláez, ; Diana Mercedes Ramírez Jiménez, ; John Jairo Zuleta Tobón, ; Carlos Enrique Yepes Delgado, Fecha de publicación : 2022 Títulos uniformes : Revista Chilena de Neuro-psiquiatría Idioma : Español (spa) Palabras clave : mental health; COVID-19 pandemic Resumen : Background: pandemic due to novel coronavirus COVID-19 has impacted on the mental health of health care workers all around the world. Material and Methods: this is a cross sectional study in which questionnaires PHQ-9 for depression, GAD-7 for anxiety, ISI-7 for insomnia were virtually and self administered by 876 health care workers laboring in hospital Pablo Tobón Uribe in Medellin city. Results: from 876 participants (29.2% physicians, 21.2% nurses and 49.5% technical nurses), 357 (40.8%) developed depressive symptoms, 300 (34.2%) anxious symptoms and 317 (36.2%) insomnia. Symptoms of depression, anxiety and insomnia were more frequently found in those who did not have basic needs satisfied and in those who felt stigmatized due to being health personal. Besides, depressive symptoms were more frequent in women, anxious symptoms in people younger than 44 years old and insomnia in divorced people. Conclusions: the frequency of mental health problems in health care workers is significant, these findings bring to light the needs for mental health attention in nurses and doctors during COVID-19 pandemic and the research of strategies to mitigate the risk on this population. Feeling stigmatized and not having basic needs satisfied were associated with symptoms of anxiety, depression and insomnia. Mención de responsabilidad : Camila Valencia A., Carolina Bernal A., Diana Mercedes Ramírez J., John Jairo Zuleta T., Carlos Enrique Yepes D. En línea : https://www.sonepsyn.cl/uploads/60-4-7.pdf Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6119 Síntomas depresivos, ansiosos e insomnio, y posibles factores asociados en personal de salud, en un Hospital General en Suramérica, durante la pandemia por COVID-19 en 2020 = Depressive and anxious symptoms and insomnia, and possible associated factors in health workers, in a General Hospital in South America, during the COVID-19 pandemic in 2020 [documento electrónico] / Camila Valencia Arbeláez, ; Carolina Bernal Arbeláez, ; Diana Mercedes Ramírez Jiménez, ; John Jairo Zuleta Tobón, ; Carlos Enrique Yepes Delgado, . - 2022.
Obra : Revista Chilena de Neuro-psiquiatría
Idioma : Español (spa)
Palabras clave : mental health; COVID-19 pandemic Resumen : Background: pandemic due to novel coronavirus COVID-19 has impacted on the mental health of health care workers all around the world. Material and Methods: this is a cross sectional study in which questionnaires PHQ-9 for depression, GAD-7 for anxiety, ISI-7 for insomnia were virtually and self administered by 876 health care workers laboring in hospital Pablo Tobón Uribe in Medellin city. Results: from 876 participants (29.2% physicians, 21.2% nurses and 49.5% technical nurses), 357 (40.8%) developed depressive symptoms, 300 (34.2%) anxious symptoms and 317 (36.2%) insomnia. Symptoms of depression, anxiety and insomnia were more frequently found in those who did not have basic needs satisfied and in those who felt stigmatized due to being health personal. Besides, depressive symptoms were more frequent in women, anxious symptoms in people younger than 44 years old and insomnia in divorced people. Conclusions: the frequency of mental health problems in health care workers is significant, these findings bring to light the needs for mental health attention in nurses and doctors during COVID-19 pandemic and the research of strategies to mitigate the risk on this population. Feeling stigmatized and not having basic needs satisfied were associated with symptoms of anxiety, depression and insomnia. Mención de responsabilidad : Camila Valencia A., Carolina Bernal A., Diana Mercedes Ramírez J., John Jairo Zuleta T., Carlos Enrique Yepes D. En línea : https://www.sonepsyn.cl/uploads/60-4-7.pdf Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6119 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001981 AC-2022-125 Archivo digital Producción Científica Artículos científicos Disponible Global PARITY: study design for a multi-centered, international point prevalence study to estimate the burden of pediatric acute critical illness in resource-limited settings / Eliana López Barón
Título : Global PARITY: study design for a multi-centered, international point prevalence study to estimate the burden of pediatric acute critical illness in resource-limited settings Tipo de documento : documento electrónico Autores : Eliana López Barón, Fecha de publicación : 2022 Títulos uniformes : Frontiers in Pediatrics Idioma : Inglés (eng) Palabras clave : pediatric critical illness acute pediatric care critical care outcome low-and lower-middle-income countries resource utilization low resource setting Resumen : Background: The burden of pediatric critical illness and resource utilization by children with critical illness in resource limited settings (RLS) are largely unknown. Without specific data that captures key aspects of critical illness, disease presentation, and resource utilization for pediatric populations in RLS, development of a contextual framework for appropriate, evidence-based interventions to guide allocation of limited but available resources is challenging. We present this methods paper which describes our efforts to determine the prevalence, etiology, hospital outcomes, and resource utilization associated with pediatric acute, critical illness in RLS globally. Methods: We will conduct a prospective, observational, multicenter, multinational point prevalence study in sixty-one participating RLS hospitals from North, Central and South America, Africa, Middle East and South Asia with four sampling time points over a 12-month period. Children aged 29 days to 14 years evaluated for acute illness or injury in an emergency department) or directly admitted to an inpatient unit will be enrolled and followed for hospital outcomes and resource utilization for the first seven days of hospitalization. The primary outcome will be prevalence of acute critical illness, which Global PARITY has defined as death within 48 hours of presentation to the hospital, including ED mortality; or admission/transfer to an HDU or ICU; or transfer to another institution for a higher level-of-care; or receiving critical care-level interventions (vasopressor infusion, invasive mechanical ventilation, non-invasive mechanical ventilation) regardless of location in the hospital, among children presenting to the hospital. Secondary outcomes include etiology of critical illness, in-hospital mortality, cause of death, resource utilization, length of hospital stay, and change in neurocognitive status. Data will be managed via REDCap, aggregated, and analyzed across sites. Discussion: This study is expected to address the current gap in understanding of the burden, etiology, resource utilization and outcomes associated with pediatric acute and critical illness in RLS. These data are crucial to inform future research and clinical management decisions and to improve global pediatric hospital outcomes. Mención de responsabilidad : Qalab Abbas, Adrian Holloway, Paula Caporal, Eliana López-Barón, Asya Agulnik, Kenneth E. Remy, John A. Appiah, Jonah Attebery, Ericka L. Fink, Jan Hau Lee, Shubhada Hooli, Niranjan Kissoon, Erika Mille, Srinivas Murthy, Fiona Muttalib, Katie Nielsen, Maria Puerto-Torres, Karla Rodrigues, Firas Sakaan, Adriana Teixeira Rodrigues, Erica A. Tabor, Amelie von Saint Andre-von Arnim, Matthew O. Wiens, William Blackwelder, David He, Teresa B. Kortz and Adnan T. Bhutta on behalf of the PALISI Global Health Subgroup the Global PARITY Investigators Referencia : Front Pediatr. 2022 Jan 28;9:793326. DOI (Digital Object Identifier) : 10.3389/fped.2021.793326 PMID : 35155314 Derechos de uso : CC BY En línea : https://www.frontiersin.org/articles/10.3389/fped.2021.793326/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6008 Global PARITY: study design for a multi-centered, international point prevalence study to estimate the burden of pediatric acute critical illness in resource-limited settings [documento electrónico] / Eliana López Barón, . - 2022.
Obra : Frontiers in Pediatrics
Idioma : Inglés (eng)
Palabras clave : pediatric critical illness acute pediatric care critical care outcome low-and lower-middle-income countries resource utilization low resource setting Resumen : Background: The burden of pediatric critical illness and resource utilization by children with critical illness in resource limited settings (RLS) are largely unknown. Without specific data that captures key aspects of critical illness, disease presentation, and resource utilization for pediatric populations in RLS, development of a contextual framework for appropriate, evidence-based interventions to guide allocation of limited but available resources is challenging. We present this methods paper which describes our efforts to determine the prevalence, etiology, hospital outcomes, and resource utilization associated with pediatric acute, critical illness in RLS globally. Methods: We will conduct a prospective, observational, multicenter, multinational point prevalence study in sixty-one participating RLS hospitals from North, Central and South America, Africa, Middle East and South Asia with four sampling time points over a 12-month period. Children aged 29 days to 14 years evaluated for acute illness or injury in an emergency department) or directly admitted to an inpatient unit will be enrolled and followed for hospital outcomes and resource utilization for the first seven days of hospitalization. The primary outcome will be prevalence of acute critical illness, which Global PARITY has defined as death within 48 hours of presentation to the hospital, including ED mortality; or admission/transfer to an HDU or ICU; or transfer to another institution for a higher level-of-care; or receiving critical care-level interventions (vasopressor infusion, invasive mechanical ventilation, non-invasive mechanical ventilation) regardless of location in the hospital, among children presenting to the hospital. Secondary outcomes include etiology of critical illness, in-hospital mortality, cause of death, resource utilization, length of hospital stay, and change in neurocognitive status. Data will be managed via REDCap, aggregated, and analyzed across sites. Discussion: This study is expected to address the current gap in understanding of the burden, etiology, resource utilization and outcomes associated with pediatric acute and critical illness in RLS. These data are crucial to inform future research and clinical management decisions and to improve global pediatric hospital outcomes. Mención de responsabilidad : Qalab Abbas, Adrian Holloway, Paula Caporal, Eliana López-Barón, Asya Agulnik, Kenneth E. Remy, John A. Appiah, Jonah Attebery, Ericka L. Fink, Jan Hau Lee, Shubhada Hooli, Niranjan Kissoon, Erika Mille, Srinivas Murthy, Fiona Muttalib, Katie Nielsen, Maria Puerto-Torres, Karla Rodrigues, Firas Sakaan, Adriana Teixeira Rodrigues, Erica A. Tabor, Amelie von Saint Andre-von Arnim, Matthew O. Wiens, William Blackwelder, David He, Teresa B. Kortz and Adnan T. Bhutta on behalf of the PALISI Global Health Subgroup the Global PARITY Investigators Referencia : Front Pediatr. 2022 Jan 28;9:793326. DOI (Digital Object Identifier) : 10.3389/fped.2021.793326 PMID : 35155314 Derechos de uso : CC BY En línea : https://www.frontiersin.org/articles/10.3389/fped.2021.793326/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6008 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001843 AC-2022-014 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-014Adobe Acrobat PDF Neglected tropical diseases and sudden cardiac death: The NET-Heart Project / Andrés Felipe Miranda Arboleda
Título : Neglected tropical diseases and sudden cardiac death: The NET-Heart Project Tipo de documento : documento electrónico Autores : Andrés Felipe Miranda Arboleda, Fecha de publicación : 2022 Títulos uniformes : Reviews in Cardiovascular Medicine Idioma : Inglés (eng) Palabras clave : neglected tropical diseases sudden cardiac death myocarditis ventricular arrhythmias Resumen : Sudden cardiac death (SCD) is responsible for approximately 6% of global mortality and 25% of cardiovascular (CV) deaths. SCD has been traditionally linked to coronary artery disease, valvular heart disease, cardiomyopathies, and genetic arrhythmia disorders. However, advancements in care for these diseases have not translated to a proportional reduction in SCD. This suggests an important role of underrecognized contributing pathologies. Neglected tropical diseases (NTDs) are a group of illnesses prevalent in tropical and sub-tropical regions which have been understudied partially due to their high prevalence in marginalized populations. The relationship between SCD and Chagas disease has been well-established, though emerging literature suggests that other NTDs with CV involvement may lead to fatal arrhythmias. Additionally, specific therapies for a subset of NTDs put patients at increased risk of malignant arrhythmias and other cardiac complications. This review aims to summarize the association between a group of selected NTDs and SCD. Mención de responsabilidad : Andrés F. Miranda-Arboleda, Luis Gerardo González-Barrera, Kiera Liblik, Juan Farina, Ezequiel José Zaidel, Clara Saldarriaga, Zier Zhou, Reem Al-Rawi, José Patricio López-López, Jorge P. Juarez-Lloclla, Shyla Gupta, Dorairaj Prabhakaran, R Krishna Kumar, Álvaro Sosa-Liprandi, Adrian Baranchuk DOI (Digital Object Identifier) : 10.31083/j.rcm2307254 Derechos de uso : CC BY En línea : https://www.imrpress.com/journal/RCM/23/7/10.31083/j.rcm2307254 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6040 Neglected tropical diseases and sudden cardiac death: The NET-Heart Project [documento electrónico] / Andrés Felipe Miranda Arboleda, . - 2022.
Obra : Reviews in Cardiovascular Medicine
Idioma : Inglés (eng)
Palabras clave : neglected tropical diseases sudden cardiac death myocarditis ventricular arrhythmias Resumen : Sudden cardiac death (SCD) is responsible for approximately 6% of global mortality and 25% of cardiovascular (CV) deaths. SCD has been traditionally linked to coronary artery disease, valvular heart disease, cardiomyopathies, and genetic arrhythmia disorders. However, advancements in care for these diseases have not translated to a proportional reduction in SCD. This suggests an important role of underrecognized contributing pathologies. Neglected tropical diseases (NTDs) are a group of illnesses prevalent in tropical and sub-tropical regions which have been understudied partially due to their high prevalence in marginalized populations. The relationship between SCD and Chagas disease has been well-established, though emerging literature suggests that other NTDs with CV involvement may lead to fatal arrhythmias. Additionally, specific therapies for a subset of NTDs put patients at increased risk of malignant arrhythmias and other cardiac complications. This review aims to summarize the association between a group of selected NTDs and SCD. Mención de responsabilidad : Andrés F. Miranda-Arboleda, Luis Gerardo González-Barrera, Kiera Liblik, Juan Farina, Ezequiel José Zaidel, Clara Saldarriaga, Zier Zhou, Reem Al-Rawi, José Patricio López-López, Jorge P. Juarez-Lloclla, Shyla Gupta, Dorairaj Prabhakaran, R Krishna Kumar, Álvaro Sosa-Liprandi, Adrian Baranchuk DOI (Digital Object Identifier) : 10.31083/j.rcm2307254 Derechos de uso : CC BY En línea : https://www.imrpress.com/journal/RCM/23/7/10.31083/j.rcm2307254 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6040 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001882 AC-2022-047 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-047Adobe Acrobat PDF Planteamiento del problema de un proyecto de investigación: escritura y formulación en ciencias de la salud / Jorge Hernando Donado Gómez
Título : Planteamiento del problema de un proyecto de investigación: escritura y formulación en ciencias de la salud Otros títulos : Problem statement in a research project: writing and formulation in the health sciences Tipo de documento : documento electrónico Autores : Jorge Hernando Donado Gómez, Fecha de publicación : 2022 Títulos uniformes : Salud Uninorte Idioma : Español (spa) Palabras clave : epidemiología investigación diseño de investigación pregunta de investigación Resumen : El planteamiento del problema de investigación es el punto de partida de toda investigación científica y es de vital importancia que se realice adecuadamente. Por esta razón, es fundamental tener claro que el desarrollo de un adecuado problema de investigación es un proceso complejo y va a estar compuesto por cinco partes. En primer lugar, se debe definir la condición clínica de interés y tener total claridad sobre ella; se recomienda escribir una pequeña descripción de la enfermedad que sirva como marco de referencia para el problema. Posteriormente, se debe expresar el problema en términos de una situación adversa o negativa (morbilidad, mortalidad, costos, entre otros), bien sea para el paciente, su familia, el sistema de salud o la sociedad. En tercer lugar, el problema de investigación implica que haya un vacío o discrepancia en el conocimiento sobre dicha situación negativa; para identificarlo, es necesario llevar a cabo una revisión sistemática de la literatura con el fin de tener presente las respuestas encontradas en investigaciones previas. Luego, se deben estimar las implicaciones o beneficios prácticos que pueda traer el resolver dicho problema. Finalmente, el problema de investigación se debe concretar de forma justificada y estructurada dando lugar a la pregunta de investigación. Además, el investigador debe estar en la capacidad de determinar si su pregunta de investigación cumple con los elementos necesarios para ser adecuada, las cuales se resumen en la mnemotecnia FINER (factible, interesante, novedosa, ética y relevante). Mención de responsabilidad : Silvia Margarita Vergara-Jaimes, Sara Botero-Bolívar, Jorge Hernando Donado Gómez DOI (Digital Object Identifier) : 10.14482/sun.38.3.610.72 En línea : https://rcientificas.uninorte.edu.co/index.php/salud/article/view/14525 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6072 Planteamiento del problema de un proyecto de investigación: escritura y formulación en ciencias de la salud = Problem statement in a research project: writing and formulation in the health sciences [documento electrónico] / Jorge Hernando Donado Gómez, . - 2022.
Obra : Salud Uninorte
Idioma : Español (spa)
Palabras clave : epidemiología investigación diseño de investigación pregunta de investigación Resumen : El planteamiento del problema de investigación es el punto de partida de toda investigación científica y es de vital importancia que se realice adecuadamente. Por esta razón, es fundamental tener claro que el desarrollo de un adecuado problema de investigación es un proceso complejo y va a estar compuesto por cinco partes. En primer lugar, se debe definir la condición clínica de interés y tener total claridad sobre ella; se recomienda escribir una pequeña descripción de la enfermedad que sirva como marco de referencia para el problema. Posteriormente, se debe expresar el problema en términos de una situación adversa o negativa (morbilidad, mortalidad, costos, entre otros), bien sea para el paciente, su familia, el sistema de salud o la sociedad. En tercer lugar, el problema de investigación implica que haya un vacío o discrepancia en el conocimiento sobre dicha situación negativa; para identificarlo, es necesario llevar a cabo una revisión sistemática de la literatura con el fin de tener presente las respuestas encontradas en investigaciones previas. Luego, se deben estimar las implicaciones o beneficios prácticos que pueda traer el resolver dicho problema. Finalmente, el problema de investigación se debe concretar de forma justificada y estructurada dando lugar a la pregunta de investigación. Además, el investigador debe estar en la capacidad de determinar si su pregunta de investigación cumple con los elementos necesarios para ser adecuada, las cuales se resumen en la mnemotecnia FINER (factible, interesante, novedosa, ética y relevante). Mención de responsabilidad : Silvia Margarita Vergara-Jaimes, Sara Botero-Bolívar, Jorge Hernando Donado Gómez DOI (Digital Object Identifier) : 10.14482/sun.38.3.610.72 En línea : https://rcientificas.uninorte.edu.co/index.php/salud/article/view/14525 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6072 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001916 AC-2022-080 Archivo digital Producción Científica Artículos científicos Disponible The Respiratory Rate-Oxygenation Index predicts failure of post-extubation high-flow nasal cannula therapy in intensive care unit patients: a retrospective cohort study / Santiago Cardona Marín
Título : The Respiratory Rate-Oxygenation Index predicts failure of post-extubation high-flow nasal cannula therapy in intensive care unit patients: a retrospective cohort study Tipo de documento : documento electrónico Autores : Santiago Cardona Marín, Fecha de publicación : 2022 Títulos uniformes : Revista Brasileira de Terapia Intensiva Idioma : Inglés (eng) Palabras clave : Cannula Oxygenation Respiratory rate Airway extubation Pneumonia Critical care Intensive care units Resumen : Objective: To investigate the applicability of the Respiratory Rate-Oxygenation Index to identify the risk of high-flow nasal cannula failure in post-extubation pneumonia patients. Methods: This was a 2-year retrospective observational study conducted in a reference hospital in Bogotá, Colombia. All patients in whom post-extubation high-flow nasal cannula therapy was used as a bridge to extubation were included in the study. The Respiratory Rate-Oxygenation Index was calculated to assess the risk of post-extubation high-flow nasal cannula failure. Results: A total of 162 patients were included in the study. Of these, 23.5% developed high-flow nasal cannula failure. The Respiratory Rate-Oxygenation Index was significantly lower in patients who had high-flow nasal cannula failure [median (IQR): 10.0 (7.7 - 14.4) versus 12.6 (10.1 - 15.6); p = 0.006]. Respiratory Rate-Oxygenation Index > 4.88 showed a crude OR of 0.23 (95%CI 0.17 - 0.30) and an adjusted OR of 0.89 (95%CI 0.81 - 0.98) stratified by severity and comorbidity. After logistic regression analysis, the Respiratory Rate-Oxygenation Index had an adjusted OR of 0.90 (95%CI 0.82 - 0.98; p = 0.026). The area under the Receiver Operating Characteristic curve for extubation failure was 0.64 (95%CI 0.53 - 0.75; p = 0.06). The Respiratory Rate-Oxygenation Index did not show differences between patients who survived and those who died during the intensive care unit stay. Conclusion: The Respiratory Rate-Oxygenation Index is an accessible tool to identify patients at risk of failing high-flow nasal cannula post-extubation treatment. Prospective studies are needed to broaden the utility in this scenario. Mención de responsabilidad : Yuli V. Fuentes, Katherine Carvajal, Santiago Cardona, Gina Sofia Montaño, Elsa D. Ibáñez-Prada, Alirio Bastidas, Eder Caceres, Ricardo Buitrago, Marcela Poveda, Luis Felipe Reyes Referencia : Rev Bras Ter Intensiva. 2022 Sep 19;34(3):360-366. DOI (Digital Object Identifier) : 10.5935/0103-507X.20220477-en PMID : 36134847 Derechos de uso : CC BY En línea : http://rbti.org.br/artigo/detalhes/0103507X-34-3-8 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6104 The Respiratory Rate-Oxygenation Index predicts failure of post-extubation high-flow nasal cannula therapy in intensive care unit patients: a retrospective cohort study [documento electrónico] / Santiago Cardona Marín, . - 2022.
Obra : Revista Brasileira de Terapia Intensiva
Idioma : Inglés (eng)
Palabras clave : Cannula Oxygenation Respiratory rate Airway extubation Pneumonia Critical care Intensive care units Resumen : Objective: To investigate the applicability of the Respiratory Rate-Oxygenation Index to identify the risk of high-flow nasal cannula failure in post-extubation pneumonia patients. Methods: This was a 2-year retrospective observational study conducted in a reference hospital in Bogotá, Colombia. All patients in whom post-extubation high-flow nasal cannula therapy was used as a bridge to extubation were included in the study. The Respiratory Rate-Oxygenation Index was calculated to assess the risk of post-extubation high-flow nasal cannula failure. Results: A total of 162 patients were included in the study. Of these, 23.5% developed high-flow nasal cannula failure. The Respiratory Rate-Oxygenation Index was significantly lower in patients who had high-flow nasal cannula failure [median (IQR): 10.0 (7.7 - 14.4) versus 12.6 (10.1 - 15.6); p = 0.006]. Respiratory Rate-Oxygenation Index > 4.88 showed a crude OR of 0.23 (95%CI 0.17 - 0.30) and an adjusted OR of 0.89 (95%CI 0.81 - 0.98) stratified by severity and comorbidity. After logistic regression analysis, the Respiratory Rate-Oxygenation Index had an adjusted OR of 0.90 (95%CI 0.82 - 0.98; p = 0.026). The area under the Receiver Operating Characteristic curve for extubation failure was 0.64 (95%CI 0.53 - 0.75; p = 0.06). The Respiratory Rate-Oxygenation Index did not show differences between patients who survived and those who died during the intensive care unit stay. Conclusion: The Respiratory Rate-Oxygenation Index is an accessible tool to identify patients at risk of failing high-flow nasal cannula post-extubation treatment. Prospective studies are needed to broaden the utility in this scenario. Mención de responsabilidad : Yuli V. Fuentes, Katherine Carvajal, Santiago Cardona, Gina Sofia Montaño, Elsa D. Ibáñez-Prada, Alirio Bastidas, Eder Caceres, Ricardo Buitrago, Marcela Poveda, Luis Felipe Reyes Referencia : Rev Bras Ter Intensiva. 2022 Sep 19;34(3):360-366. DOI (Digital Object Identifier) : 10.5935/0103-507X.20220477-en PMID : 36134847 Derechos de uso : CC BY En línea : http://rbti.org.br/artigo/detalhes/0103507X-34-3-8 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6104 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001952 AC-2022-113 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-113Adobe Acrobat PDF
Título : Primary non-gestational choriocarcinoma of the uterine cervix Tipo de documento : documento electrónico Autores : Gabriel Jaime Varela Aguirre, Fecha de publicación : 2022 Títulos uniformes : International Journal of Gynecological Cancer Idioma : Inglés (eng) Palabras clave : cervix uteri gynecology pathology trophoblastic neoplasms Mención de responsabilidad : Camilo Andrés Pérez Montiel, Gabriel Jaime Varela Aguirre Referencia : Int J Gynecol Cancer. 2022 Jan;32(1):111-112. DOI (Digital Object Identifier) : 10.1136/ijgc-2021-003061 PMID : 34980664 En línea : https://ijgc.bmj.com/content/32/1/111.long Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5999 Primary non-gestational choriocarcinoma of the uterine cervix [documento electrónico] / Gabriel Jaime Varela Aguirre, . - 2022.
Obra : International Journal of Gynecological Cancer
Idioma : Inglés (eng)
Palabras clave : cervix uteri gynecology pathology trophoblastic neoplasms Mención de responsabilidad : Camilo Andrés Pérez Montiel, Gabriel Jaime Varela Aguirre Referencia : Int J Gynecol Cancer. 2022 Jan;32(1):111-112. DOI (Digital Object Identifier) : 10.1136/ijgc-2021-003061 PMID : 34980664 En línea : https://ijgc.bmj.com/content/32/1/111.long Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5999 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001980 AC-2022-005 Archivo digital Producción Científica Artículos científicos Disponible Ataxia with ocular apraxia type 1 (AOA1) (APTX, W279* Mutation): neurological, neuropsychological, and molecular outlining of a heterogenous phenotype in four Colombian Siblings / Dora Lilia Hernández López
Título : Ataxia with ocular apraxia type 1 (AOA1) (APTX, W279* Mutation): neurological, neuropsychological, and molecular outlining of a heterogenous phenotype in four Colombian Siblings Tipo de documento : documento electrónico Autores : Dora Lilia Hernández López, Fecha de publicación : 2022 Títulos uniformes : Molecular Neurobiology Idioma : Inglés (eng) Palabras clave : AOA1 APTX Ataxia with ocular apraxia type 1 C2H2-type zinc fingers Colombia Latino population W279* mutation Resumen : Hereditary ataxias are a group of devastating neurological disorders that affect coordination of gait and are often associated with poor coordination of hands, speech, and eye movements. Ataxia with ocular apraxia type 1 (AOA1) (OMIM: 606,350.0006) is characterized by slowly progressive symptoms of childhood-onset and pathogenic mutations in APTX; the only known cause underpinning AOA1. APTX encodes the protein aprataxin, composed of three domains sharing homology with proteins involved in DNA damage, signaling, and repair. We present four siblings from an endogamic family in a rural, isolated town of Colombia with ataxia and ocular apraxia of childhood-onset and confirmed molecular diagnosis of AOA1, homozygous for the W279* p.Trp279Ter mutation. We predicted the mutated APTX with AlphaFold to demonstrate the effects of this stop-gain mutation that deletes three beta helices encoded by amino acid 270 to 339 rescinding the C2H2-type zinc fingers (Znf) (C2H2 Znf) DNA-binding, the DNA-repair domain, and the whole 3D structure of APTX. All siblings exhibited different ages of onset (4, 6, 8, and 11 years old) and heterogeneous patterns of dysarthria (ranging from absence to mild-moderate dysarthria). Neuropsychological evaluation showed no neurocognitive impairment in three siblings, but one sibling showed temporospatial disorientation, semantic and phonologic fluency impairment, episodic memory affection, constructional apraxia, moderate anomia, low executive function, and symptoms of depression. To our knowledge, this report represents the most extensive series of siblings affected with AOA1 in Latin America, and the genetic analysis completed adds important knowledge to outline this family's disease and general complex phenotype of hereditary ataxias. Mención de responsabilidad : David Aguillon, Daniel Vasquez, Lucia Madrigal, Sonia Moreno, Dora Hernández, Mario Isaza-Ruget, Juan Javier Lopez, Iván Landires, Virginia Nuñez-Samudio, Carlos M. Restrepo, Oscar M. Vidal, Jorge I. Vélez, Mauricio Arcos-Holzinger, Francisco Lopera & Mauricio Arcos-Burgos Referencia : Mol Neurobiol. 2022 Jun;59(6):3845-3858. DOI (Digital Object Identifier) : 10.1007/s12035-022-02821-7 PMID : 35420381 En línea : https://link.springer.com/article/10.1007/s12035-022-02821-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6031 Ataxia with ocular apraxia type 1 (AOA1) (APTX, W279* Mutation): neurological, neuropsychological, and molecular outlining of a heterogenous phenotype in four Colombian Siblings [documento electrónico] / Dora Lilia Hernández López, . - 2022.
Obra : Molecular Neurobiology
Idioma : Inglés (eng)
Palabras clave : AOA1 APTX Ataxia with ocular apraxia type 1 C2H2-type zinc fingers Colombia Latino population W279* mutation Resumen : Hereditary ataxias are a group of devastating neurological disorders that affect coordination of gait and are often associated with poor coordination of hands, speech, and eye movements. Ataxia with ocular apraxia type 1 (AOA1) (OMIM: 606,350.0006) is characterized by slowly progressive symptoms of childhood-onset and pathogenic mutations in APTX; the only known cause underpinning AOA1. APTX encodes the protein aprataxin, composed of three domains sharing homology with proteins involved in DNA damage, signaling, and repair. We present four siblings from an endogamic family in a rural, isolated town of Colombia with ataxia and ocular apraxia of childhood-onset and confirmed molecular diagnosis of AOA1, homozygous for the W279* p.Trp279Ter mutation. We predicted the mutated APTX with AlphaFold to demonstrate the effects of this stop-gain mutation that deletes three beta helices encoded by amino acid 270 to 339 rescinding the C2H2-type zinc fingers (Znf) (C2H2 Znf) DNA-binding, the DNA-repair domain, and the whole 3D structure of APTX. All siblings exhibited different ages of onset (4, 6, 8, and 11 years old) and heterogeneous patterns of dysarthria (ranging from absence to mild-moderate dysarthria). Neuropsychological evaluation showed no neurocognitive impairment in three siblings, but one sibling showed temporospatial disorientation, semantic and phonologic fluency impairment, episodic memory affection, constructional apraxia, moderate anomia, low executive function, and symptoms of depression. To our knowledge, this report represents the most extensive series of siblings affected with AOA1 in Latin America, and the genetic analysis completed adds important knowledge to outline this family's disease and general complex phenotype of hereditary ataxias. Mención de responsabilidad : David Aguillon, Daniel Vasquez, Lucia Madrigal, Sonia Moreno, Dora Hernández, Mario Isaza-Ruget, Juan Javier Lopez, Iván Landires, Virginia Nuñez-Samudio, Carlos M. Restrepo, Oscar M. Vidal, Jorge I. Vélez, Mauricio Arcos-Holzinger, Francisco Lopera & Mauricio Arcos-Burgos Referencia : Mol Neurobiol. 2022 Jun;59(6):3845-3858. DOI (Digital Object Identifier) : 10.1007/s12035-022-02821-7 PMID : 35420381 En línea : https://link.springer.com/article/10.1007/s12035-022-02821-7 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6031 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001872 AC-2022-037 Archivo digital Producción Científica Artículos científicos Disponible Lente multifocal de tres piezas con captura de la óptica, como manejo de ruptura de la cápsula posterior en paciente sometida a cirugía facorrefractiva / Yeliana Mailyn Valencia Gómez
Título : Lente multifocal de tres piezas con captura de la óptica, como manejo de ruptura de la cápsula posterior en paciente sometida a cirugía facorrefractiva Otros títulos : Three-piece multifocal intraocular lens with optic capture as management of posterior capsule rupture in a patient undergoing refractive lens exchange Tipo de documento : documento electrónico Autores : Yeliana Mailyn Valencia Gómez, Fecha de publicación : 2022 Títulos uniformes : Revista de la Sociedad Colombiana de Oftalmología Idioma : Español (spa) Palabras clave : Lentes intraoculares multifocales Cápsula posterior Ruptura Resumen : Se presenta el caso de una paciente sometida a cirugía facorrefractiva que sufre una ruptura de la cápsula posterior en la cirugía del primer ojo. Ante la imposibilidad de usar un lente trifocal de una pieza como inicialmente se tenía planteado, se realiza implante de lente multifocal de tres piezas en el sulcus con captura pupilar. Se reportan las imágenes de Scheimpflug y de retroiluminación del lente de tres piezas de un ojo y el lente de una pieza del ojo contralateral. Mención de responsabilidad : Kepa Balparda, Yeliana M. Valencia-Gómez, Ma. Alejandra Nicholls-Molina y Tatiana Herrera-Chalarca DOI (Digital Object Identifier) : 10.24875/RSCO.22000024 Derechos de uso : CC BY-NC-ND En línea : https://www.revistasco.com/frame_esp.php?id=44 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6063 Lente multifocal de tres piezas con captura de la óptica, como manejo de ruptura de la cápsula posterior en paciente sometida a cirugía facorrefractiva = Three-piece multifocal intraocular lens with optic capture as management of posterior capsule rupture in a patient undergoing refractive lens exchange [documento electrónico] / Yeliana Mailyn Valencia Gómez, . - 2022.
Obra : Revista de la Sociedad Colombiana de Oftalmología
Idioma : Español (spa)
Palabras clave : Lentes intraoculares multifocales Cápsula posterior Ruptura Resumen : Se presenta el caso de una paciente sometida a cirugía facorrefractiva que sufre una ruptura de la cápsula posterior en la cirugía del primer ojo. Ante la imposibilidad de usar un lente trifocal de una pieza como inicialmente se tenía planteado, se realiza implante de lente multifocal de tres piezas en el sulcus con captura pupilar. Se reportan las imágenes de Scheimpflug y de retroiluminación del lente de tres piezas de un ojo y el lente de una pieza del ojo contralateral. Mención de responsabilidad : Kepa Balparda, Yeliana M. Valencia-Gómez, Ma. Alejandra Nicholls-Molina y Tatiana Herrera-Chalarca DOI (Digital Object Identifier) : 10.24875/RSCO.22000024 Derechos de uso : CC BY-NC-ND En línea : https://www.revistasco.com/frame_esp.php?id=44 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6063 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001907 AC-2022-071 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-071Adobe Acrobat PDF R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation / Sergio Iván Hoyos Duque
Título : R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation Tipo de documento : documento electrónico Autores : Sergio Iván Hoyos Duque, Fecha de publicación : 2022 Títulos uniformes : JHEP Reports Idioma : Inglés (eng) Resumen : Background & aims: Patients with hepatocellular carcinoma (HCC) are selected for liver transplantation (LT) based on pre-LT imaging ± alpha-foetoprotein (AFP) level, but discrepancies between pre-LT tumour assessment and explant are frequent. Our aim was to design an explant-based recurrence risk reassessment score to refine prediction of recurrence after LT and provide a framework to guide post-LT management. Methods: Adult patients who underwent transplantation between 2000 and 2018 for HCC in 47 centres were included. A prediction model for recurrence was developed using competing-risk regression analysis in a European training cohort (TC; n = 1,359) and tested in a Latin American validation cohort (VC; n=1,085). Results: In the TC, 76.4% of patients with HCC met the Milan criteria, and 89.9% had an AFP score of ≤2 points. The recurrence risk reassessment (R3)-AFP model was designed based on variables independently associated with recurrence in the TC (with associated weights): ≥4 nodules (sub-distribution of hazard ratio [SHR] = 1.88, 1 point), size of largest nodule (3-6 cm: SHR = 1.83, 1 point; >6 cm: SHR = 5.82, 5 points), presence of microvascular invasion (MVI; SHR = 2.69, 2 points), nuclear grade >II (SHR = 1.20, 1 point), and last pre-LT AFP value (101-1,000 ng/ml: SHR = 1.57, 1 point; >1,000 ng/ml: SHR = 2.83, 2 points). Wolber's c-index was 0.76 (95% CI 0.72-0.80), significantly superior to an R3 model without AFP (0.75; 95% CI 0.72-0.79; p = 0.01). Four 5-year recurrence risk categories were identified: very low (score = 0; 5.5%), low (1-2 points; 15.1%), high (3-6 points; 39.1%), and very high (>6 points; 73.9%). The R3-AFP score performed well in the VC (Wolber's c-index of 0.78; 95% CI 0.73-0.83). Conclusions: The R3 score including the last pre-LT AFP value (R3-AFP score) provides a user-friendly, standardised framework to design post-LT surveillance strategies, protocols, or adjuvant therapy trials for HCC not limited to the Milan criteria. Mención de responsabilidad : Charlotte Costentin, Federico Piñero, Helena Degroote, Andrea Notarpaolo, Ilka F. Boin, Karim Boudjema, Cinzia Baccaro, Luis G. Podestá, Philippe Bachellier, Giuseppe Maria Ettorre, Jaime Poniachik, Fabrice Muscari, Fabrizio Dibenedetto, Sergio Hoyos Duque, Ephrem Salame, Umberto Cillo, Sebastian Marciano, Claire Vanlemmens, Stefano Fagiuoli, Patrizia Burra, Hans Van Vlierberghe, Daniel Cherqui, Quirino Lai, Marcelo Silva, Fernando Rubinstein, Christophe Duvoux Referencia : JHEP Rep. 2022 Feb 2;4(5):100445. DOI (Digital Object Identifier) : 10.1016/j.jhepr.2022.100445 PMID : 35360522 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S2589555922000179 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6095 R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation [documento electrónico] / Sergio Iván Hoyos Duque, . - 2022.
Obra : JHEP Reports
Idioma : Inglés (eng)
Resumen : Background & aims: Patients with hepatocellular carcinoma (HCC) are selected for liver transplantation (LT) based on pre-LT imaging ± alpha-foetoprotein (AFP) level, but discrepancies between pre-LT tumour assessment and explant are frequent. Our aim was to design an explant-based recurrence risk reassessment score to refine prediction of recurrence after LT and provide a framework to guide post-LT management. Methods: Adult patients who underwent transplantation between 2000 and 2018 for HCC in 47 centres were included. A prediction model for recurrence was developed using competing-risk regression analysis in a European training cohort (TC; n = 1,359) and tested in a Latin American validation cohort (VC; n=1,085). Results: In the TC, 76.4% of patients with HCC met the Milan criteria, and 89.9% had an AFP score of ≤2 points. The recurrence risk reassessment (R3)-AFP model was designed based on variables independently associated with recurrence in the TC (with associated weights): ≥4 nodules (sub-distribution of hazard ratio [SHR] = 1.88, 1 point), size of largest nodule (3-6 cm: SHR = 1.83, 1 point; >6 cm: SHR = 5.82, 5 points), presence of microvascular invasion (MVI; SHR = 2.69, 2 points), nuclear grade >II (SHR = 1.20, 1 point), and last pre-LT AFP value (101-1,000 ng/ml: SHR = 1.57, 1 point; >1,000 ng/ml: SHR = 2.83, 2 points). Wolber's c-index was 0.76 (95% CI 0.72-0.80), significantly superior to an R3 model without AFP (0.75; 95% CI 0.72-0.79; p = 0.01). Four 5-year recurrence risk categories were identified: very low (score = 0; 5.5%), low (1-2 points; 15.1%), high (3-6 points; 39.1%), and very high (>6 points; 73.9%). The R3-AFP score performed well in the VC (Wolber's c-index of 0.78; 95% CI 0.73-0.83). Conclusions: The R3 score including the last pre-LT AFP value (R3-AFP score) provides a user-friendly, standardised framework to design post-LT surveillance strategies, protocols, or adjuvant therapy trials for HCC not limited to the Milan criteria. Mención de responsabilidad : Charlotte Costentin, Federico Piñero, Helena Degroote, Andrea Notarpaolo, Ilka F. Boin, Karim Boudjema, Cinzia Baccaro, Luis G. Podestá, Philippe Bachellier, Giuseppe Maria Ettorre, Jaime Poniachik, Fabrice Muscari, Fabrizio Dibenedetto, Sergio Hoyos Duque, Ephrem Salame, Umberto Cillo, Sebastian Marciano, Claire Vanlemmens, Stefano Fagiuoli, Patrizia Burra, Hans Van Vlierberghe, Daniel Cherqui, Quirino Lai, Marcelo Silva, Fernando Rubinstein, Christophe Duvoux Referencia : JHEP Rep. 2022 Feb 2;4(5):100445. DOI (Digital Object Identifier) : 10.1016/j.jhepr.2022.100445 PMID : 35360522 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S2589555922000179 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6095 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001943 AC-2022-104 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-104Adobe Acrobat PDF Association of cancer diagnosis and therapeutic stage with mortality in pediatric patients with COVID-19, prospective multicenter cohort study from Latin America / Alejandro Díaz Díaz ; Mónica Rosa Trujillo Honeysberg
Título : Association of cancer diagnosis and therapeutic stage with mortality in pediatric patients with COVID-19, prospective multicenter cohort study from Latin America Tipo de documento : documento electrónico Autores : Alejandro Díaz Díaz, ; Mónica Rosa Trujillo Honeysberg, Fecha de publicación : 2022 Títulos uniformes : Frontiers in Pediatrics Idioma : Inglés (eng) Palabras clave : pediatric cancer pediatric COVID-19 child development PICU (pediatric intensive care unit) Resumen : Background: Children with cancer are at risk of critical disease and mortality from COVID-19 infection. In this study, we describe the clinical characteristics of pediatric patients with cancer and COVID-19 from multiple Latin American centers and risk factors associated with mortality in this population. Methods: This study is a multicenter, prospective cohort study conducted at 12 hospitals from 6 Latin American countries (Argentina, Bolivia, Colombia, Ecuador, Honduras and Peru) from April to November 2021. Patients younger than 14 years of age that had an oncological diagnosis and COVID-19 or multisystemic inflammatory syndrome in children (MIS-C) who were treated in the inpatient setting were included. The primary exposure was the diagnosis and treatment status, and the primary outcome was mortality. We defined “new diagnosis” as patients with no previous diagnosis of cancer, “established diagnosis” as patients with cancer and ongoing treatment and “relapse” as patients with cancer and ongoing treatment that had a prior cancer-free period. A frequentist analysis was performed including a multivariate logistic regression for mortality. Results: Two hundred and ten patients were included in the study; 30 (14%) died during the study period and 67% of patients who died were admitted to critical care. Demographics were similar in survivors and non-survivors. Patients with low weight for age ( Mención de responsabilidad : Jesus Ángel Dominguez-Rojas, Pablo Vásquez-Hoyos, Rodrigo Pérez-Morales, Ana María Monsalve-Quintero, Lupe Mora-Robles, Alejandro Diaz-Diaz, Silvio Fabio Torres, Ángel Castro-Dajer, Lizeth Yuliana Cabanillas-Burgos, Vladimir Aguilera-Avendaño, Edwin Mauricio Cantillano-Quintero, Anna Camporesi, Asya Agulnik, Sheena Mukkada, Giancarlo Alvarado-Gamarra, Ninoska Rojas-Soto, Ana Luisa Mendieta-Zevallos, Mariela Violeta Tello-Pezo, Liliana Vásquez-Ponce, Rubén Eduardo Lasso-Palomino, María Camila Pérez-Arroyave, Mónica Trujillo-Honeysberg, Juan Gonzalo Mesa-Monsalve, Carlos Alberto Pardo González, Juan Francisco López Cubillos, Sebastián Gonzalez-Dambrauskas and Alvaro Coronado-Munoz Referencia : Front Pediatr. 2022 May 3;10:885633. DOI (Digital Object Identifier) : 10.3389/fped.2022.885633 PMID : 35592840 Derechos de uso : CC BY En línea : https://www.frontiersin.org/articles/10.3389/fped.2022.885633/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6022 Association of cancer diagnosis and therapeutic stage with mortality in pediatric patients with COVID-19, prospective multicenter cohort study from Latin America [documento electrónico] / Alejandro Díaz Díaz, ; Mónica Rosa Trujillo Honeysberg, . - 2022.
Obra : Frontiers in Pediatrics
Idioma : Inglés (eng)
Palabras clave : pediatric cancer pediatric COVID-19 child development PICU (pediatric intensive care unit) Resumen : Background: Children with cancer are at risk of critical disease and mortality from COVID-19 infection. In this study, we describe the clinical characteristics of pediatric patients with cancer and COVID-19 from multiple Latin American centers and risk factors associated with mortality in this population. Methods: This study is a multicenter, prospective cohort study conducted at 12 hospitals from 6 Latin American countries (Argentina, Bolivia, Colombia, Ecuador, Honduras and Peru) from April to November 2021. Patients younger than 14 years of age that had an oncological diagnosis and COVID-19 or multisystemic inflammatory syndrome in children (MIS-C) who were treated in the inpatient setting were included. The primary exposure was the diagnosis and treatment status, and the primary outcome was mortality. We defined “new diagnosis” as patients with no previous diagnosis of cancer, “established diagnosis” as patients with cancer and ongoing treatment and “relapse” as patients with cancer and ongoing treatment that had a prior cancer-free period. A frequentist analysis was performed including a multivariate logistic regression for mortality. Results: Two hundred and ten patients were included in the study; 30 (14%) died during the study period and 67% of patients who died were admitted to critical care. Demographics were similar in survivors and non-survivors. Patients with low weight for age ( Mención de responsabilidad : Jesus Ángel Dominguez-Rojas, Pablo Vásquez-Hoyos, Rodrigo Pérez-Morales, Ana María Monsalve-Quintero, Lupe Mora-Robles, Alejandro Diaz-Diaz, Silvio Fabio Torres, Ángel Castro-Dajer, Lizeth Yuliana Cabanillas-Burgos, Vladimir Aguilera-Avendaño, Edwin Mauricio Cantillano-Quintero, Anna Camporesi, Asya Agulnik, Sheena Mukkada, Giancarlo Alvarado-Gamarra, Ninoska Rojas-Soto, Ana Luisa Mendieta-Zevallos, Mariela Violeta Tello-Pezo, Liliana Vásquez-Ponce, Rubén Eduardo Lasso-Palomino, María Camila Pérez-Arroyave, Mónica Trujillo-Honeysberg, Juan Gonzalo Mesa-Monsalve, Carlos Alberto Pardo González, Juan Francisco López Cubillos, Sebastián Gonzalez-Dambrauskas and Alvaro Coronado-Munoz Referencia : Front Pediatr. 2022 May 3;10:885633. DOI (Digital Object Identifier) : 10.3389/fped.2022.885633 PMID : 35592840 Derechos de uso : CC BY En línea : https://www.frontiersin.org/articles/10.3389/fped.2022.885633/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6022 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001862 AC-2022-028 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-028Adobe Acrobat PDF El índice de fragilidad y sus características en ensayos clínicos aleatorizados de diabetes mellitus / Jorge Hernando Donado Gómez
Título : El índice de fragilidad y sus características en ensayos clínicos aleatorizados de diabetes mellitus Otros títulos : The Fragility Index and its characteristics in randomized clinical trials of diabetes mellitus Tipo de documento : documento electrónico Autores : Jorge Hernando Donado Gómez, Fecha de publicación : 2022 Títulos uniformes : CES Medicina Idioma : Español (spa) Palabras clave : índice de fragilidad diabetes mellitus ensayos clínicos controlados Resumen : Introducción: para valorar la robustez de los resultados se ha propuesto una herramienta llamada el Índice de Fragilidad (IF), esta se define como el mínimo número de pacientes que se tienen que cambiar de “No eventos” a “Eventos” en el grupo de intervención para que un resultado estadísticamente significativo pase a no significativo, evidenciando que entre menor sea el IF, los resultados serán más frágiles. Diferentes autores han encontrado que la significancia de los resultados de muchos Ensayos Clínicos Controlados (ECA) dependen de pocos eventos. El objetivo del estudio fue evaluar el IF de los ECA en diabetes mellitus de cinco de las revistas médicas de mayor impacto a nivel mundial. Metodología: se realizó búsqueda electrónica en PubMed, para identificar ECA en Annals of Internal Medicine, BMJ, The Lancet, The New England Journal of Medicine y JAMA. Se revisaron los ECA en pacientes con diabetes mellitus o prediabetes y se calculó el IF para cada desenlace según el método descrito por Walsh et al, usando tablas de contingencia 2x2. Se planeó usar el coeficiente de correlación de Spearman para evaluar la correlación entre el IF y el tamaño de la muestra, el número de eventos, el valor de p y el tiempo de seguimiento. Se evaluó la significancia de todos los resultados con un valor de p Mención de responsabilidad : David Benavides-Zora, Sara Vásquez-Martínez, Jorge Hernando Donado Gómez Referencia : CES med ; 36(2): 106-121, mayo-ago. 2022. DOI (Digital Object Identifier) : 10.21615/cesmedicina.6632 Derechos de uso : CC BY-NC-SA En línea : https://revistas.ces.edu.co/index.php/medicina/article/view/6632 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6054 El índice de fragilidad y sus características en ensayos clínicos aleatorizados de diabetes mellitus = The Fragility Index and its characteristics in randomized clinical trials of diabetes mellitus [documento electrónico] / Jorge Hernando Donado Gómez, . - 2022.
Obra : CES Medicina
Idioma : Español (spa)
Palabras clave : índice de fragilidad diabetes mellitus ensayos clínicos controlados Resumen : Introducción: para valorar la robustez de los resultados se ha propuesto una herramienta llamada el Índice de Fragilidad (IF), esta se define como el mínimo número de pacientes que se tienen que cambiar de “No eventos” a “Eventos” en el grupo de intervención para que un resultado estadísticamente significativo pase a no significativo, evidenciando que entre menor sea el IF, los resultados serán más frágiles. Diferentes autores han encontrado que la significancia de los resultados de muchos Ensayos Clínicos Controlados (ECA) dependen de pocos eventos. El objetivo del estudio fue evaluar el IF de los ECA en diabetes mellitus de cinco de las revistas médicas de mayor impacto a nivel mundial. Metodología: se realizó búsqueda electrónica en PubMed, para identificar ECA en Annals of Internal Medicine, BMJ, The Lancet, The New England Journal of Medicine y JAMA. Se revisaron los ECA en pacientes con diabetes mellitus o prediabetes y se calculó el IF para cada desenlace según el método descrito por Walsh et al, usando tablas de contingencia 2x2. Se planeó usar el coeficiente de correlación de Spearman para evaluar la correlación entre el IF y el tamaño de la muestra, el número de eventos, el valor de p y el tiempo de seguimiento. Se evaluó la significancia de todos los resultados con un valor de p Mención de responsabilidad : David Benavides-Zora, Sara Vásquez-Martínez, Jorge Hernando Donado Gómez Referencia : CES med ; 36(2): 106-121, mayo-ago. 2022. DOI (Digital Object Identifier) : 10.21615/cesmedicina.6632 Derechos de uso : CC BY-NC-SA En línea : https://revistas.ces.edu.co/index.php/medicina/article/view/6632 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6054 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001898 AC-2022-062 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-062Adobe Acrobat PDF Etiology and risk factors for admission to the pediatric intensive care unit in children with encephalitis in a developing country / Mónica Rosa Trujillo Honeysberg
Título : Etiology and risk factors for admission to the pediatric intensive care unit in children with encephalitis in a developing country Tipo de documento : documento electrónico Autores : Mónica Rosa Trujillo Honeysberg, Fecha de publicación : 2022 Títulos uniformes : Pediatric Infectious Disease Journal Idioma : Inglés (eng) Palabras clave : Encephalitis risk factors PICU etiology children Resumen : Objective: To describe a cohort of pediatric patients with encephalitis and their risk factors for admission to the pediatric intensive care unit (PICU). Study Design: Children ( Mención de responsabilidad : Guerrero, María P. MD; Romero, Andrés F. MD; Luengas, Miguel MD; Dávalos, Diana M. MD, MPH, DrPH; Mesa-Monsalve, Juan Gonzalo MD; Vivas-Trochez, Rosalba MD; Camacho-Moreno, German MD; Trujillo-Valencia, Mónica MD; Giraldo, Juan P. Calle MD; Mejía, Luis F. MD; Rojas-Hernández, Juan P. MD, MSc; Vinasco, Nathaly MD; Racines, Andrea Ruiz MD; Meléndez, Alejandro MD; Beltrán, Claudia P. MD; López, Pio MD; Chaucanez, Yamile MD; Patiño, Jaime MD; Rodríguez, Wilfrido Coronell MD, PhD; Salgado, Doris MD; Martínez, Marly MD; Restrepo, Andrea MD; Márquez, Kelly MD; Galvis, Diego MD; Benavidez, Iván MD; Rojas, Christian A. MD; Cantor, Erika MSC; López Medina, Eduardo MD, MSc Referencia : Pediatr Infect Dis J. 2022 Oct 1;41(10):806-812. DOI (Digital Object Identifier) : 10.1097/INF.0000000000003637 PMID : 35830514 En línea : https://journals.lww.com/pidj/Abstract/2022/10000/Etiology_and_Risk_Factors_for_ [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6086 Etiology and risk factors for admission to the pediatric intensive care unit in children with encephalitis in a developing country [documento electrónico] / Mónica Rosa Trujillo Honeysberg, . - 2022.
Obra : Pediatric Infectious Disease Journal
Idioma : Inglés (eng)
Palabras clave : Encephalitis risk factors PICU etiology children Resumen : Objective: To describe a cohort of pediatric patients with encephalitis and their risk factors for admission to the pediatric intensive care unit (PICU). Study Design: Children ( Mención de responsabilidad : Guerrero, María P. MD; Romero, Andrés F. MD; Luengas, Miguel MD; Dávalos, Diana M. MD, MPH, DrPH; Mesa-Monsalve, Juan Gonzalo MD; Vivas-Trochez, Rosalba MD; Camacho-Moreno, German MD; Trujillo-Valencia, Mónica MD; Giraldo, Juan P. Calle MD; Mejía, Luis F. MD; Rojas-Hernández, Juan P. MD, MSc; Vinasco, Nathaly MD; Racines, Andrea Ruiz MD; Meléndez, Alejandro MD; Beltrán, Claudia P. MD; López, Pio MD; Chaucanez, Yamile MD; Patiño, Jaime MD; Rodríguez, Wilfrido Coronell MD, PhD; Salgado, Doris MD; Martínez, Marly MD; Restrepo, Andrea MD; Márquez, Kelly MD; Galvis, Diego MD; Benavidez, Iván MD; Rojas, Christian A. MD; Cantor, Erika MSC; López Medina, Eduardo MD, MSc Referencia : Pediatr Infect Dis J. 2022 Oct 1;41(10):806-812. DOI (Digital Object Identifier) : 10.1097/INF.0000000000003637 PMID : 35830514 En línea : https://journals.lww.com/pidj/Abstract/2022/10000/Etiology_and_Risk_Factors_for_ [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6086 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001933 AC-2022-094 Archivo digital Producción Científica Artículos científicos Disponible Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: a Latin American perspective / Kenny Mauricio Gálvez Cárdenas
Título : Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: a Latin American perspective Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Fecha de publicación : 2022 Títulos uniformes : Clinical and Applied Thrombosis/Hemostasis Idioma : Inglés (eng) Palabras clave : anticoagulation cancer venous thromboembolism Resumen : Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. On the basis of results from randomized controlled trials, direct oral anticoagulants (DOACs) are now recommended for the treatment of cancer-associated VTE. The decision to use a DOAC requires consideration of bleeding risk, particularly in patients with gastrointestinal (GI) malignancies, the cost-benefit and convenience of oral therapy, and patient preference. While efficacy with apixaban, edoxaban, and rivaroxaban versus dalteparin has been consistent in the treatment of cancer-associated VTE, heterogeneity is evident with respect to major GI bleeding, with an increased risk with edoxaban and rivaroxaban but not apixaban. Although cost and accessibility vary in different countries of Latin America, DOACs should be considered for the long-term treatment of cancer-associated VTE in all patients who are likely to benefit. Apixaban may be the preferred DOAC in patients with GI malignancies and LMWH may be preferred for patients with upper or unresected lower GI tumors. Vitamin K antagonists should only be used for anticoagulation when DOACs and low molecular weight heparin are inaccessible or unsuitable. Mención de responsabilidad : Rodrigo Abensur Athanazio, José Manuel Ceresetto, Luis Javier Marfil Rivera, Gabriela Cesarman-Maus, Kenny Galvez, Marcos Arêas Marques, Aldo Hugo Tabares, Carlos Alberto Ortiz Santacruz, Fernando Costa Santini, Luis Corrales, Alexander T Cohen Referencia : Clin Appl Thromb Hemost. Jan-Dec 2022;28:10760296221082988. DOI (Digital Object Identifier) : 10.1177/10760296221082988 PMID : 35261295 Derechos de uso : CC BY-NC En línea : https://journals.sagepub.com/doi/10.1177/10760296221082988 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6013 Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: a Latin American perspective [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, . - 2022.
Obra : Clinical and Applied Thrombosis/Hemostasis
Idioma : Inglés (eng)
Palabras clave : anticoagulation cancer venous thromboembolism Resumen : Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. On the basis of results from randomized controlled trials, direct oral anticoagulants (DOACs) are now recommended for the treatment of cancer-associated VTE. The decision to use a DOAC requires consideration of bleeding risk, particularly in patients with gastrointestinal (GI) malignancies, the cost-benefit and convenience of oral therapy, and patient preference. While efficacy with apixaban, edoxaban, and rivaroxaban versus dalteparin has been consistent in the treatment of cancer-associated VTE, heterogeneity is evident with respect to major GI bleeding, with an increased risk with edoxaban and rivaroxaban but not apixaban. Although cost and accessibility vary in different countries of Latin America, DOACs should be considered for the long-term treatment of cancer-associated VTE in all patients who are likely to benefit. Apixaban may be the preferred DOAC in patients with GI malignancies and LMWH may be preferred for patients with upper or unresected lower GI tumors. Vitamin K antagonists should only be used for anticoagulation when DOACs and low molecular weight heparin are inaccessible or unsuitable. Mención de responsabilidad : Rodrigo Abensur Athanazio, José Manuel Ceresetto, Luis Javier Marfil Rivera, Gabriela Cesarman-Maus, Kenny Galvez, Marcos Arêas Marques, Aldo Hugo Tabares, Carlos Alberto Ortiz Santacruz, Fernando Costa Santini, Luis Corrales, Alexander T Cohen Referencia : Clin Appl Thromb Hemost. Jan-Dec 2022;28:10760296221082988. DOI (Digital Object Identifier) : 10.1177/10760296221082988 PMID : 35261295 Derechos de uso : CC BY-NC En línea : https://journals.sagepub.com/doi/10.1177/10760296221082988 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6013 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001850 AC-2022-019 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-019Adobe Acrobat PDF
Título : Enfermedad hepatobiliar asociada a COVID-19 Otros títulos : Hepatobiliary disease associated with COVID-19 Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2022 Títulos uniformes : Hepatología Idioma : Español (spa) Palabras clave : COVID-19 SARS-CoV-2 hígado hepatopatías vacunas Resumen : La enfermedad COVID-19, causada por el coronavirus tipo 2 (SARS-CoV-2), ha tenido un gran impacto en la salud a nivel mundial. A pesar de considerarse una enfermedad principalmente respiratoria, el virus SARS-CoV-2 también es responsable de otro tipo de manifestaciones extrapulmonares, como son las enfermedades hepatobiliares. En esta revisión se describen los posibles mecanismos de patogénesis implicados en la lesión hepática causada por el SARS-CoV-2. Adicionalmente, se analiza la relación entre COVID-19 y la enfermedad hepática crónica, las implicaciones que tiene en el carcinoma hepatocelular y en el trasplante hepático, así como las recomendaciones para la vacunación contra el SARS-CoV-2 en los pacientes afectados por enfermedad hepática. Por último, se proponen algunas estrategias para superar el reto al que se enfrenta el médico en el manejo de los pacientes con enfermedades hepatobiliares y COVID-19. Mención de responsabilidad : Juan Carlos Restrepo-Gutiérrez, Ana Isabel Toro-Montoya Referencia : Hepatología ; 3(2): 143-154, 2022. DOI (Digital Object Identifier) : 10.52784/27112330.155 Derechos de uso : CC BY-NC-ND En línea : https://revistahepatologia.com/index.php/hepa/article/view/56 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6045 Enfermedad hepatobiliar asociada a COVID-19 = Hepatobiliary disease associated with COVID-19 [documento electrónico] / Juan Carlos Restrepo Gutiérrez, . - 2022.
Obra : Hepatología
Idioma : Español (spa)
Palabras clave : COVID-19 SARS-CoV-2 hígado hepatopatías vacunas Resumen : La enfermedad COVID-19, causada por el coronavirus tipo 2 (SARS-CoV-2), ha tenido un gran impacto en la salud a nivel mundial. A pesar de considerarse una enfermedad principalmente respiratoria, el virus SARS-CoV-2 también es responsable de otro tipo de manifestaciones extrapulmonares, como son las enfermedades hepatobiliares. En esta revisión se describen los posibles mecanismos de patogénesis implicados en la lesión hepática causada por el SARS-CoV-2. Adicionalmente, se analiza la relación entre COVID-19 y la enfermedad hepática crónica, las implicaciones que tiene en el carcinoma hepatocelular y en el trasplante hepático, así como las recomendaciones para la vacunación contra el SARS-CoV-2 en los pacientes afectados por enfermedad hepática. Por último, se proponen algunas estrategias para superar el reto al que se enfrenta el médico en el manejo de los pacientes con enfermedades hepatobiliares y COVID-19. Mención de responsabilidad : Juan Carlos Restrepo-Gutiérrez, Ana Isabel Toro-Montoya Referencia : Hepatología ; 3(2): 143-154, 2022. DOI (Digital Object Identifier) : 10.52784/27112330.155 Derechos de uso : CC BY-NC-ND En línea : https://revistahepatologia.com/index.php/hepa/article/view/56 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6045 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001887 AC-2022-052 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-052Adobe Acrobat PDF Disseminated fusariosis in children: Report of two cases in girls with leukemia / Andrea Victoria Restrepo Gouzy ; Mónica Rosa Trujillo Honeysberg
Título : Disseminated fusariosis in children: Report of two cases in girls with leukemia Tipo de documento : documento electrónico Autores : Andrea Victoria Restrepo Gouzy, ; Mónica Rosa Trujillo Honeysberg, Fecha de publicación : 2022 Títulos uniformes : Current Medical Mycology Idioma : Inglés (eng) Palabras clave : Invasive fungal infection Leukemia Neutropenia Fusarium spp Resumen : Background and purpose: Disseminated fusariosis is an opportunistic infection caused by the hyaline fungus Fusarium spp. and occurs mainly in patients with leukemia. Case report: Two cases of disseminated fusariosis in pediatric patients are presented. Profound and prolonged neutropenia, fever, myalgia, and skin lesions in the legs were present in two girls with leukemia undergoing chemotherapy. In the first case, infection by Fusarium spp. was confirmed by anatomopathological findings, pathogen isolation, and polymerase chain reaction. In the second case, Fusarium solani infection was confirmed by mass spectrometry using blood cultures and skin lesion samples. Conclusion: It is important to consider disseminated fusariosis in high-risk patients who present with profound and prolonged neutropenia and persistent fever that does not resolve after broad-spectrum antibiotics to initiate antifungal therapy in a timely manner. Mención de responsabilidad : Alixandra De La Espriella, Andrea Restrepo, Monica Trujillo, Karen Arango Referencia : Curr Med Mycol. 2022 Mar;8(1):39-43. DOI (Digital Object Identifier) : 10.18502/cmm.8.1.9213 PMID : 36340435 Derechos de uso : CC BY En línea : http://cmm.mazums.ac.ir/article_141948.html Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6077 Disseminated fusariosis in children: Report of two cases in girls with leukemia [documento electrónico] / Andrea Victoria Restrepo Gouzy, ; Mónica Rosa Trujillo Honeysberg, . - 2022.
Obra : Current Medical Mycology
Idioma : Inglés (eng)
Palabras clave : Invasive fungal infection Leukemia Neutropenia Fusarium spp Resumen : Background and purpose: Disseminated fusariosis is an opportunistic infection caused by the hyaline fungus Fusarium spp. and occurs mainly in patients with leukemia. Case report: Two cases of disseminated fusariosis in pediatric patients are presented. Profound and prolonged neutropenia, fever, myalgia, and skin lesions in the legs were present in two girls with leukemia undergoing chemotherapy. In the first case, infection by Fusarium spp. was confirmed by anatomopathological findings, pathogen isolation, and polymerase chain reaction. In the second case, Fusarium solani infection was confirmed by mass spectrometry using blood cultures and skin lesion samples. Conclusion: It is important to consider disseminated fusariosis in high-risk patients who present with profound and prolonged neutropenia and persistent fever that does not resolve after broad-spectrum antibiotics to initiate antifungal therapy in a timely manner. Mención de responsabilidad : Alixandra De La Espriella, Andrea Restrepo, Monica Trujillo, Karen Arango Referencia : Curr Med Mycol. 2022 Mar;8(1):39-43. DOI (Digital Object Identifier) : 10.18502/cmm.8.1.9213 PMID : 36340435 Derechos de uso : CC BY En línea : http://cmm.mazums.ac.ir/article_141948.html Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6077 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001922 AC-2022-085 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-085Adobe Acrobat PDF
Título : Diagnóstico de sarcoidosis a partir de compromiso ocular. Reporte de caso Otros títulos : Sarcoidosis diagnosis based on ocular involvement. Case report Tipo de documento : documento electrónico Autores : Mónica Ortíz Pérez, Fecha de publicación : 2022 Títulos uniformes : Revista Colombiana de Reumatología Idioma : Español (spa) Palabras clave : Sarcoidosis Granuloma Biopsia Conjuntiva Resumen : La sarcoidosis es una enfermedad multisistémica de causa desconocida, secundaria a una reacción inmunitaria determinada genéticamente y desencadenada por factores ambientales, que conlleva la formación de granulomas no caseosos. El compromiso ocular es el segundo más frecuente después del pulmonar. El hallazgo más común es la uveítis granulomatosa anterior; también se puede evidenciar uveítis posterior, periflebitis retiniana, coriorretinitis, conjuntivitis, escleritis y neuritis óptica. Describimos el caso de una paciente pediátrica con una enfermedad de compromiso multisistémico de larga data, en quien la demostración de granulomas no caseificantes en la biopsia conjuntival permitió establecer el diagnóstico presuntivo de sarcoidosis. Mención de responsabilidad : Juan Camilo Cadavid Usuga, Mónica Ortiz Pérez, Marcos Restrepo Arango y Ana María Montufar Pantoja DOI (Digital Object Identifier) : 10.1016/j.rcreu.2022.03.005 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0121812322000287 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6109 Diagnóstico de sarcoidosis a partir de compromiso ocular. Reporte de caso = Sarcoidosis diagnosis based on ocular involvement. Case report [documento electrónico] / Mónica Ortíz Pérez, . - 2022.
Obra : Revista Colombiana de Reumatología
Idioma : Español (spa)
Palabras clave : Sarcoidosis Granuloma Biopsia Conjuntiva Resumen : La sarcoidosis es una enfermedad multisistémica de causa desconocida, secundaria a una reacción inmunitaria determinada genéticamente y desencadenada por factores ambientales, que conlleva la formación de granulomas no caseosos. El compromiso ocular es el segundo más frecuente después del pulmonar. El hallazgo más común es la uveítis granulomatosa anterior; también se puede evidenciar uveítis posterior, periflebitis retiniana, coriorretinitis, conjuntivitis, escleritis y neuritis óptica. Describimos el caso de una paciente pediátrica con una enfermedad de compromiso multisistémico de larga data, en quien la demostración de granulomas no caseificantes en la biopsia conjuntival permitió establecer el diagnóstico presuntivo de sarcoidosis. Mención de responsabilidad : Juan Camilo Cadavid Usuga, Mónica Ortiz Pérez, Marcos Restrepo Arango y Ana María Montufar Pantoja DOI (Digital Object Identifier) : 10.1016/j.rcreu.2022.03.005 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0121812322000287 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6109 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001960 AC-2022-121 Archivo digital Producción Científica Artículos científicos Disponible Deficiencia de lipasa ácida lisosomal, una enfermedad subdiagnosticada. Reporte de caso / Suad Siuffi Campo ; Ricardo Londoño García ; Juan Camilo Pérez Cadavid ; Octavio Germán Muñoz Maya
Título : Deficiencia de lipasa ácida lisosomal, una enfermedad subdiagnosticada. Reporte de caso Otros títulos : Lysosomal acid lipase deficiency, an underdiagnosed disease. Case report Tipo de documento : documento electrónico Autores : Suad Siuffi Campo, ; Ricardo Londoño García, ; Juan Camilo Pérez Cadavid, ; Octavio Germán Muñoz Maya, Fecha de publicación : 2022 Títulos uniformes : Hepatología Idioma : Español (spa) Palabras clave : lipasa metabolismo de los lípidos enfermedad de acumulación de colesterol éster dislipidemia hepatomegalia cirrosis hígado graso Resumen : La deficiencia de lipasa ácida lisosomal (LAL-D) es una enfermedad rara de herencia autosómica recesiva, causada por mutaciones en el gen LIPA, localizado en el cromosoma 10 (10q23.31), la cual causa el acúmulo sistémico y progresivo de ésteres de colesterol y triglicéridos. Se han reportado más de 40 mutaciones en dicho gen, por lo cual las manifestaciones clínicas de la enfermedad son diversas, predominando la hepatopatía y la enfermedad cardiovascular de aparición temprana. Se han descrito pocos casos a nivel mundial de esta enfermedad. En este reporte se expone el caso de un paciente con LAL-D, quien inicialmente fue tratado como glucogenosis. Más tarde, se confirmaron las alteraciones en los lípidos séricos, la deficiencia de la enzima, así como la mutación correspondiente a dicha deficiencia enzimática. Mención de responsabilidad : Suad Siuffi-Campo, Ricardo Londoño-García, Juan Camilo Pérez-Cadavid, Octavio G. Muñoz-Maya Referencia : Hepatología ; 3(1): 97-105, 2022. DOI (Digital Object Identifier) : 10.52784/27112330.151 Derechos de uso : CC BY-NC-ND En línea : https://revistahepatologia.com/index.php/hepa/article/view/52 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6004 Deficiencia de lipasa ácida lisosomal, una enfermedad subdiagnosticada. Reporte de caso = Lysosomal acid lipase deficiency, an underdiagnosed disease. Case report [documento electrónico] / Suad Siuffi Campo, ; Ricardo Londoño García, ; Juan Camilo Pérez Cadavid, ; Octavio Germán Muñoz Maya, . - 2022.
Obra : Hepatología
Idioma : Español (spa)
Palabras clave : lipasa metabolismo de los lípidos enfermedad de acumulación de colesterol éster dislipidemia hepatomegalia cirrosis hígado graso Resumen : La deficiencia de lipasa ácida lisosomal (LAL-D) es una enfermedad rara de herencia autosómica recesiva, causada por mutaciones en el gen LIPA, localizado en el cromosoma 10 (10q23.31), la cual causa el acúmulo sistémico y progresivo de ésteres de colesterol y triglicéridos. Se han reportado más de 40 mutaciones en dicho gen, por lo cual las manifestaciones clínicas de la enfermedad son diversas, predominando la hepatopatía y la enfermedad cardiovascular de aparición temprana. Se han descrito pocos casos a nivel mundial de esta enfermedad. En este reporte se expone el caso de un paciente con LAL-D, quien inicialmente fue tratado como glucogenosis. Más tarde, se confirmaron las alteraciones en los lípidos séricos, la deficiencia de la enzima, así como la mutación correspondiente a dicha deficiencia enzimática. Mención de responsabilidad : Suad Siuffi-Campo, Ricardo Londoño-García, Juan Camilo Pérez-Cadavid, Octavio G. Muñoz-Maya Referencia : Hepatología ; 3(1): 97-105, 2022. DOI (Digital Object Identifier) : 10.52784/27112330.151 Derechos de uso : CC BY-NC-ND En línea : https://revistahepatologia.com/index.php/hepa/article/view/52 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6004 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001838 AC-2022-010 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-010Adobe Acrobat PDF Infusión subcutánea continua de morfina en paciente con disnea tumoral avanzada. Reporte de caso y revisión de la literatura / Jhon Lidemberto Cárdenas Cárdenas
Título : Infusión subcutánea continua de morfina en paciente con disnea tumoral avanzada. Reporte de caso y revisión de la literatura Otros títulos : Continuous subcutaneous infusion of morphine in a patient with advanced tumor dyspnea. Case report and literature review Tipo de documento : documento electrónico Autores : Jhon Lidemberto Cárdenas Cárdenas, Fecha de publicación : 2022 Títulos uniformes : Revista Colombiana de Cancerología Idioma : Español (spa) Palabras clave : disnea cáncer opioides infusion subcutánea Resumen : Se plantea un caso clínico en un paciente con disnea tumoral asociada a una enfermedad oncológica avanzada y en progresión que requiere manejo sintomático y que precisó de diferentes estrategias farmacológicas, alcanzando mayor beneficio con la administración de opioides a través de infusión subcutánea continua. Se hace al final una revisión en el manejo de la disnea tumoral con énfasis en la utilidad de este tipo de estrategia comparándola con otras disponibles. Mención de responsabilidad : John Lidemberto Cardenas Cardenas DOI (Digital Object Identifier) : 10.35509/01239015.794 Derechos de uso : CC BY-NC-ND En línea : https://www.revistacancercol.org/index.php/cancer/article/view/794 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6036 Infusión subcutánea continua de morfina en paciente con disnea tumoral avanzada. Reporte de caso y revisión de la literatura = Continuous subcutaneous infusion of morphine in a patient with advanced tumor dyspnea. Case report and literature review [documento electrónico] / Jhon Lidemberto Cárdenas Cárdenas, . - 2022.
Obra : Revista Colombiana de Cancerología
Idioma : Español (spa)
Palabras clave : disnea cáncer opioides infusion subcutánea Resumen : Se plantea un caso clínico en un paciente con disnea tumoral asociada a una enfermedad oncológica avanzada y en progresión que requiere manejo sintomático y que precisó de diferentes estrategias farmacológicas, alcanzando mayor beneficio con la administración de opioides a través de infusión subcutánea continua. Se hace al final una revisión en el manejo de la disnea tumoral con énfasis en la utilidad de este tipo de estrategia comparándola con otras disponibles. Mención de responsabilidad : John Lidemberto Cardenas Cardenas DOI (Digital Object Identifier) : 10.35509/01239015.794 Derechos de uso : CC BY-NC-ND En línea : https://www.revistacancercol.org/index.php/cancer/article/view/794 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6036 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001878 AC-2022-043 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-043Adobe Acrobat PDF Resultados del manejo no operatorio en trauma hepático de los pacientes que se presentaron al servicio de urgencias del Hospital San Vicente Fundación, Medellín / David Alejandro Mejía Toro
Título : Resultados del manejo no operatorio en trauma hepático de los pacientes que se presentaron al servicio de urgencias del Hospital San Vicente Fundación, Medellín Otros títulos : Outcomes of non-operative management of liver trauma in patients who presented to the Emergency Department of Hospital San Vicente Fundación, Medellín Tipo de documento : documento electrónico Autores : David Alejandro Mejía Toro, Fecha de publicación : 2022 Títulos uniformes : Revista Colombiana de Cirugía Idioma : Español (spa) Palabras clave : hígado heridas y traumatismos trauma cerrado procedimientos quirúrgicos tratamiento conservador mortalidad Resumen : Introducción. El hígado continúa siendo uno de los órganos más afectados en los pacientes con trauma. Su evaluación y manejo han cambiado sustancialmente con los avances tecnológicos en cuanto a diagnóstico y las técnicas de manejo menos invasivas. El objetivo de este estudio fue realizar un análisis de los resultados del manejo no operatorio del trauma hepático en cuanto a incidencia, eficacia, morbimortalidad, necesidad de intervención quirúrgica, tasa y factores relacionados con el fallo del manejo no operatorio. Métodos. Se realizó un estudio descriptivo observacional retrospectivo, analizando pacientes con trauma hepático confirmado con tomografía o cirugía, durante un periodo de 72 meses, en el Hospital Universitario San Vicente Fundación, un centro de IV nivel de atención, en Medellín, Colombia. Resultados. Se incluyeron 341 pacientes con trauma hepático, 224 por trauma penetrante y 117 por trauma cerrado. En trauma penetrante, 208 pacientes fueron llevados a cirugía inmediatamente, el resto fueron manejados de manera no operatoria, con una falla en el manejo en 20 pacientes. En trauma cerrado, 22 fueron llevados a cirugía inmediata y 95 sometidos a manejo no operatorio, con una falla en 9 pacientes. La mortalidad global fue de 9,7 % y la mortalidad relacionada al trauma hepático fue de 4,4 %. El grado del trauma, el índice de severidad del trauma y las lesiones abdominales no hepáticas no se consideraron factores de riesgo para la falla del manejo no operatorio. Conclusiones. El manejo no operatorio continúa siendo una alternativa segura y efectiva para pacientes con trauma hepático, sobretodo en trauma cerrado. En trauma penetrante se debe realizar una adecuada selección de los pacientes. Mención de responsabilidad : Marcela Cadavid-Navas, Daniela Valdés-Giraldo, David Alejandro Mejía-Toro, Juan Camilo Correa-Cote, Carlos Hernando Morales-Uribe, Carlos Andrés Delgado-López Referencia : Rev. colomb. cir ; 37(3): 417-427, junio 14, 2022. DOI (Digital Object Identifier) : 10.30944/20117582.1116 Derechos de uso : CC BY-NC-ND En línea : https://www.revistacirugia.org/index.php/cirugia/article/view/1116 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6068 Resultados del manejo no operatorio en trauma hepático de los pacientes que se presentaron al servicio de urgencias del Hospital San Vicente Fundación, Medellín = Outcomes of non-operative management of liver trauma in patients who presented to the Emergency Department of Hospital San Vicente Fundación, Medellín [documento electrónico] / David Alejandro Mejía Toro, . - 2022.
Obra : Revista Colombiana de Cirugía
Idioma : Español (spa)
Palabras clave : hígado heridas y traumatismos trauma cerrado procedimientos quirúrgicos tratamiento conservador mortalidad Resumen : Introducción. El hígado continúa siendo uno de los órganos más afectados en los pacientes con trauma. Su evaluación y manejo han cambiado sustancialmente con los avances tecnológicos en cuanto a diagnóstico y las técnicas de manejo menos invasivas. El objetivo de este estudio fue realizar un análisis de los resultados del manejo no operatorio del trauma hepático en cuanto a incidencia, eficacia, morbimortalidad, necesidad de intervención quirúrgica, tasa y factores relacionados con el fallo del manejo no operatorio. Métodos. Se realizó un estudio descriptivo observacional retrospectivo, analizando pacientes con trauma hepático confirmado con tomografía o cirugía, durante un periodo de 72 meses, en el Hospital Universitario San Vicente Fundación, un centro de IV nivel de atención, en Medellín, Colombia. Resultados. Se incluyeron 341 pacientes con trauma hepático, 224 por trauma penetrante y 117 por trauma cerrado. En trauma penetrante, 208 pacientes fueron llevados a cirugía inmediatamente, el resto fueron manejados de manera no operatoria, con una falla en el manejo en 20 pacientes. En trauma cerrado, 22 fueron llevados a cirugía inmediata y 95 sometidos a manejo no operatorio, con una falla en 9 pacientes. La mortalidad global fue de 9,7 % y la mortalidad relacionada al trauma hepático fue de 4,4 %. El grado del trauma, el índice de severidad del trauma y las lesiones abdominales no hepáticas no se consideraron factores de riesgo para la falla del manejo no operatorio. Conclusiones. El manejo no operatorio continúa siendo una alternativa segura y efectiva para pacientes con trauma hepático, sobretodo en trauma cerrado. En trauma penetrante se debe realizar una adecuada selección de los pacientes. Mención de responsabilidad : Marcela Cadavid-Navas, Daniela Valdés-Giraldo, David Alejandro Mejía-Toro, Juan Camilo Correa-Cote, Carlos Hernando Morales-Uribe, Carlos Andrés Delgado-López Referencia : Rev. colomb. cir ; 37(3): 417-427, junio 14, 2022. DOI (Digital Object Identifier) : 10.30944/20117582.1116 Derechos de uso : CC BY-NC-ND En línea : https://www.revistacirugia.org/index.php/cirugia/article/view/1116 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6068 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001912 AC-2022-076 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-076Adobe Acrobat PDF A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial / Sergio Álvarez Vallejo
Título : A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial Tipo de documento : documento electrónico Autores : Sergio Álvarez Vallejo, Fecha de publicación : 2022 Títulos uniformes : Alzheimer's & Dementia Idioma : Inglés (eng) Palabras clave : Alzheimer’s disease amyloid antibody data sharing magnetic resonance imaging positron emission tomography presenilin 1 primary prevention secondary prevention Resumen : Introduction: The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease (API ADAD) Trial evaluated the anti-oligomeric amyloid beta (Aβ) antibody therapy crenezumab in cognitively unimpaired members of the Colombian presenilin 1 (PSEN1) E280A kindred. We report availability, methods employed to protect confidentiality and anonymity of participants, and process for requesting and accessing baseline data. Methods: We developed mechanisms to share baseline data from the API ADAD Trial in consultation with experts and other groups sharing data from Alzheimer's disease (AD) prevention trials, balancing the need to protect anonymity and trial integrity with making data broadly available to accelerate progress in the field. We pressure-tested deliberate and inadvertent potential threats under specific assumptions, employed a system to suppress or mask both direct and indirect identifying variables, limited and firewalled data managers, and put forth specific principles requisite to receive data. Results: Baseline demographic, PSEN1 E280A and apolipoprotein E genotypes, florbetapir and fluorodeoxyglucose positron emission tomography, magnetic resonance imaging, clinical, and cognitive data can now be requested by interested researchers. Discussion: Baseline data are publicly available; treatment data and biological samples, including baseline and treatment-related blood-based biomarker data will become available in accordance with our original trial agreement and subsequently developed Collaboration for Alzheimer's Prevention principles. Sharing of these data will allow exploration of important questions including the differential effects of initiating an investigational AD prevention therapy both before as well as after measurable Aβ plaque deposition. Mención de responsabilidad : Eric M. Reiman, Jeremy J. Pruzin, Silvia Rios-Romenets, Chris Brown, Margarita Giraldo, Natalia Acosta-Baena, Carlos Tobon, Nan Hu, Yinghua Chen, Valentina Ghisays, Jessica Enos, Dhruman D. Goradia, Wendy Lee, Ji Luo, Michael Malek-Ahmadi, Hillary Protas, Ronald G. Thomas, Kewei Chen, Yi Su, Connie Boker, Diego Mastroeni, Sergio Alvarez, Yakeel T. Quiroz, Jessica B. Langbaum, Kaycee M. Sink, Francisco Lopera, Pierre N. Tariot, and the API ADAD Colombia Trial Group Referencia : Alzheimers Dement. 2022 Nov 14. DOI (Digital Object Identifier) : 10.1002/alz.12843 PMID : 36373344 Derechos de uso : CC BY-NC En línea : https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12843 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6100 A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial [documento electrónico] / Sergio Álvarez Vallejo, . - 2022.
Obra : Alzheimer's & Dementia
Idioma : Inglés (eng)
Palabras clave : Alzheimer’s disease amyloid antibody data sharing magnetic resonance imaging positron emission tomography presenilin 1 primary prevention secondary prevention Resumen : Introduction: The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease (API ADAD) Trial evaluated the anti-oligomeric amyloid beta (Aβ) antibody therapy crenezumab in cognitively unimpaired members of the Colombian presenilin 1 (PSEN1) E280A kindred. We report availability, methods employed to protect confidentiality and anonymity of participants, and process for requesting and accessing baseline data. Methods: We developed mechanisms to share baseline data from the API ADAD Trial in consultation with experts and other groups sharing data from Alzheimer's disease (AD) prevention trials, balancing the need to protect anonymity and trial integrity with making data broadly available to accelerate progress in the field. We pressure-tested deliberate and inadvertent potential threats under specific assumptions, employed a system to suppress or mask both direct and indirect identifying variables, limited and firewalled data managers, and put forth specific principles requisite to receive data. Results: Baseline demographic, PSEN1 E280A and apolipoprotein E genotypes, florbetapir and fluorodeoxyglucose positron emission tomography, magnetic resonance imaging, clinical, and cognitive data can now be requested by interested researchers. Discussion: Baseline data are publicly available; treatment data and biological samples, including baseline and treatment-related blood-based biomarker data will become available in accordance with our original trial agreement and subsequently developed Collaboration for Alzheimer's Prevention principles. Sharing of these data will allow exploration of important questions including the differential effects of initiating an investigational AD prevention therapy both before as well as after measurable Aβ plaque deposition. Mención de responsabilidad : Eric M. Reiman, Jeremy J. Pruzin, Silvia Rios-Romenets, Chris Brown, Margarita Giraldo, Natalia Acosta-Baena, Carlos Tobon, Nan Hu, Yinghua Chen, Valentina Ghisays, Jessica Enos, Dhruman D. Goradia, Wendy Lee, Ji Luo, Michael Malek-Ahmadi, Hillary Protas, Ronald G. Thomas, Kewei Chen, Yi Su, Connie Boker, Diego Mastroeni, Sergio Alvarez, Yakeel T. Quiroz, Jessica B. Langbaum, Kaycee M. Sink, Francisco Lopera, Pierre N. Tariot, and the API ADAD Colombia Trial Group Referencia : Alzheimers Dement. 2022 Nov 14. DOI (Digital Object Identifier) : 10.1002/alz.12843 PMID : 36373344 Derechos de uso : CC BY-NC En línea : https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12843 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6100 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001948 AC-2022-109 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-109Adobe Acrobat PDF COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature / Juan Carlos Restrepo Gutiérrez
Título : COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2022 Títulos uniformes : Journal of Translational Autoimmunity Idioma : Inglés (eng) Palabras clave : Autoimmune hepatitis COVID-19 SARS-CoV-2 AstraZeneca ChAdOx1 nCoV-19 AZD1222 Resumen : Autoimmunity following COVID-19 vaccination has been reported. Herein, a 79-year-old man with clinical and immunological features of autoimmune hepatitis type 1 after ChAdOx1 nCoV-19 vaccination is presented. Clinical manifestations rapidly remitted after the instauration of immunomodulatory management. This case, together with a comprehensive review of the literature, illustrates the association between COVID-19 vaccines and the development of autoimmune conditions. Mención de responsabilidad : Laura Camacho-Domínguez, Yhojan Rodríguez, Fernando Polo, Juan Carlos Restrepo Gutierrez, Elizabeth Zapata, Manuel Rojas, Juan-Manuel Anaya Referencia : J Transl Autoimmun. 2022;5:100140. DOI (Digital Object Identifier) : 10.1016/j.jtauto.2022.100140 PMID : 35013724 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S2589909022000016 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5995 COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature [documento electrónico] / Juan Carlos Restrepo Gutiérrez, . - 2022.
Obra : Journal of Translational Autoimmunity
Idioma : Inglés (eng)
Palabras clave : Autoimmune hepatitis COVID-19 SARS-CoV-2 AstraZeneca ChAdOx1 nCoV-19 AZD1222 Resumen : Autoimmunity following COVID-19 vaccination has been reported. Herein, a 79-year-old man with clinical and immunological features of autoimmune hepatitis type 1 after ChAdOx1 nCoV-19 vaccination is presented. Clinical manifestations rapidly remitted after the instauration of immunomodulatory management. This case, together with a comprehensive review of the literature, illustrates the association between COVID-19 vaccines and the development of autoimmune conditions. Mención de responsabilidad : Laura Camacho-Domínguez, Yhojan Rodríguez, Fernando Polo, Juan Carlos Restrepo Gutierrez, Elizabeth Zapata, Manuel Rojas, Juan-Manuel Anaya Referencia : J Transl Autoimmun. 2022;5:100140. DOI (Digital Object Identifier) : 10.1016/j.jtauto.2022.100140 PMID : 35013724 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S2589909022000016 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5995 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001779 AC-2022-001 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-001Adobe Acrobat PDF Short-term effectiveness and reduction in insulin requirements in patients with type 2 diabetes treated With IdegLira in a real-world setting / Carlos Esteban Builes Montaño
Título : Short-term effectiveness and reduction in insulin requirements in patients with type 2 diabetes treated With IdegLira in a real-world setting Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, Fecha de publicación : 2022 Títulos uniformes : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : type 2 diabetes insulin degludec liraglutide IDegLira real-world evidence (RWE) Resumen : Background: Type 2 diabetes mellitus (T2DM) is a chronic, highly prevalent disease with a significant impact on health. Appropriate treatment requires effective and timely escalation to achieve metabolic control. To evaluate the effectiveness and safety of IDegLira on adults with T2DM previously treated with oral antidiabetics and/or insulin in a real-life setting. Methods: An observational study in a real-world setting was conducted. Patients were selected from the outpatient clinic of two centers dedicated to specialized diabetes care. Main outcomes were HbA1c, body weight, insulin dose changes, hypoglycemia, and other adverse events. Results: 67 T2DM patients treated with IDegLira were monitored between 3 and 7 months. At the end of foll ow-up, the median change in HbA1c was -1.05% (CI95% -1.45, -0.65), and a decrease in insulin requirement was also observed (mean difference -10 TDD units (CI95% - 17 to -2.5). No treatment discontinuation was reported, hypoglycemia events were reported in 3 patients at the end of follow-up versus 8 patients at baseline. Conclusions: This real-life study shows the effectiveness in glycemic control of IDegLira use in T2DM patients who do not achieve goals with other therapies, with an adequate safety profile. The findings need to be confirmed with evaluation of therapeutic results in larger cohorts. Mención de responsabilidad : Alex Ramírez-Rincón, Carlos E. Builes-Montaño, Jaime A. Hincapié-García, Victor M. Blanco, José F. Botero-Arango Referencia : Front Endocrinol (Lausanne). 2022 Apr 28;13:828607. DOI (Digital Object Identifier) : 10.3389/fendo.2022.828607 PMID : 35573995 Derechos de uso : CC BY En línea : https://www.frontiersin.org/articles/10.3389/fendo.2022.828607/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6027 Short-term effectiveness and reduction in insulin requirements in patients with type 2 diabetes treated With IdegLira in a real-world setting [documento electrónico] / Carlos Esteban Builes Montaño, . - 2022.
Obra : Frontiers in Endocrinology
Idioma : Inglés (eng)
Palabras clave : type 2 diabetes insulin degludec liraglutide IDegLira real-world evidence (RWE) Resumen : Background: Type 2 diabetes mellitus (T2DM) is a chronic, highly prevalent disease with a significant impact on health. Appropriate treatment requires effective and timely escalation to achieve metabolic control. To evaluate the effectiveness and safety of IDegLira on adults with T2DM previously treated with oral antidiabetics and/or insulin in a real-life setting. Methods: An observational study in a real-world setting was conducted. Patients were selected from the outpatient clinic of two centers dedicated to specialized diabetes care. Main outcomes were HbA1c, body weight, insulin dose changes, hypoglycemia, and other adverse events. Results: 67 T2DM patients treated with IDegLira were monitored between 3 and 7 months. At the end of foll ow-up, the median change in HbA1c was -1.05% (CI95% -1.45, -0.65), and a decrease in insulin requirement was also observed (mean difference -10 TDD units (CI95% - 17 to -2.5). No treatment discontinuation was reported, hypoglycemia events were reported in 3 patients at the end of follow-up versus 8 patients at baseline. Conclusions: This real-life study shows the effectiveness in glycemic control of IDegLira use in T2DM patients who do not achieve goals with other therapies, with an adequate safety profile. The findings need to be confirmed with evaluation of therapeutic results in larger cohorts. Mención de responsabilidad : Alex Ramírez-Rincón, Carlos E. Builes-Montaño, Jaime A. Hincapié-García, Victor M. Blanco, José F. Botero-Arango Referencia : Front Endocrinol (Lausanne). 2022 Apr 28;13:828607. DOI (Digital Object Identifier) : 10.3389/fendo.2022.828607 PMID : 35573995 Derechos de uso : CC BY En línea : https://www.frontiersin.org/articles/10.3389/fendo.2022.828607/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6027 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001868 AC-2022-033 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-033Adobe Acrobat PDF Early stimulated thyroglobulin after thyroidectomy for thyroid cancer predicts pre-radioiodine therapy thyroglobulin values / Julio Andrés Valencia Ferro
Título : Early stimulated thyroglobulin after thyroidectomy for thyroid cancer predicts pre-radioiodine therapy thyroglobulin values Tipo de documento : documento electrónico Autores : Julio Andrés Valencia Ferro, Fecha de publicación : 2022 Títulos uniformes : Minerva Endocrinology Idioma : Inglés (eng) Palabras clave : Thyroid neoplasms Thyroglobulin Thyroidectomy Resumen : Introduction: Follow-up of patients who undergo a total thyroidectomy is performed with thyroglobulin (Tg), and anti-thyroglobulin antibodies (AbTg). The objective of RAI adjuvant therapy is to negativize Tg to undetectable levels to ease the follow-up. The objective of this study was to evaluate the correlation of serum Tg values measured 2 weeks after surgery with the Tg value prior to RAI adjuvant therapy in order to define its utility as a reliable predictor of pre-therapy Tg and as a potential predictor to avoid RAI adjuvant therapy. Methods: Retrospective analysis of a cohort recruited prospectively. Adult patients with thyroid carcinoma who underwent total thyroidectomy and classified as intermediate or high risk by ATA guidelines. All patients were left without levothyroxine support after surgery and for at least two weeks. We measured biochemical markers two-four weeks after thyroidectomy and before and after RAI. Results: We included 75 patients. Thirty-three (44.0%) patients were classified as ATA high risk. In the post-RAI scan, only 1 (1.3%) showed distant metastases. The comparison between early post-operative and pre-therapy Tg values showed that Tg decreased or remained stable at postoperative levels in 75 patients (100%). Conclusions: Postoperative Tg measurements are a reliable marker of pretherapy Tg levels in patients with intermediate- and high-risk thyroid carcinoma who are candidates for RAI adjuvant therapy. These results need correlation with outcomes and response to therapy in high-risk patients. Mención de responsabilidad : Julio Valencia, Jorge Jiménez, Alvaro Sanabria Referencia : Minerva Endocrinol (Torino). 2022 Jul 13. DOI (Digital Object Identifier) : 10.23736/S2724-6507.22.03813-1 PMID : 35822431 En línea : https://www.minervamedica.it/en/journals/minerva-endocrinology/article.php?cod=R [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6059 Early stimulated thyroglobulin after thyroidectomy for thyroid cancer predicts pre-radioiodine therapy thyroglobulin values [documento electrónico] / Julio Andrés Valencia Ferro, . - 2022.
Obra : Minerva Endocrinology
Idioma : Inglés (eng)
Palabras clave : Thyroid neoplasms Thyroglobulin Thyroidectomy Resumen : Introduction: Follow-up of patients who undergo a total thyroidectomy is performed with thyroglobulin (Tg), and anti-thyroglobulin antibodies (AbTg). The objective of RAI adjuvant therapy is to negativize Tg to undetectable levels to ease the follow-up. The objective of this study was to evaluate the correlation of serum Tg values measured 2 weeks after surgery with the Tg value prior to RAI adjuvant therapy in order to define its utility as a reliable predictor of pre-therapy Tg and as a potential predictor to avoid RAI adjuvant therapy. Methods: Retrospective analysis of a cohort recruited prospectively. Adult patients with thyroid carcinoma who underwent total thyroidectomy and classified as intermediate or high risk by ATA guidelines. All patients were left without levothyroxine support after surgery and for at least two weeks. We measured biochemical markers two-four weeks after thyroidectomy and before and after RAI. Results: We included 75 patients. Thirty-three (44.0%) patients were classified as ATA high risk. In the post-RAI scan, only 1 (1.3%) showed distant metastases. The comparison between early post-operative and pre-therapy Tg values showed that Tg decreased or remained stable at postoperative levels in 75 patients (100%). Conclusions: Postoperative Tg measurements are a reliable marker of pretherapy Tg levels in patients with intermediate- and high-risk thyroid carcinoma who are candidates for RAI adjuvant therapy. These results need correlation with outcomes and response to therapy in high-risk patients. Mención de responsabilidad : Julio Valencia, Jorge Jiménez, Alvaro Sanabria Referencia : Minerva Endocrinol (Torino). 2022 Jul 13. DOI (Digital Object Identifier) : 10.23736/S2724-6507.22.03813-1 PMID : 35822431 En línea : https://www.minervamedica.it/en/journals/minerva-endocrinology/article.php?cod=R [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6059 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001903 AC-2022-067 Archivo digital Producción Científica Artículos científicos Disponible Performance of pre-transplant criteria in prediction of hepatocellular carcinoma progression and waitlist dropout / Sergio Iván Hoyos Duque
Título : Performance of pre-transplant criteria in prediction of hepatocellular carcinoma progression and waitlist dropout Tipo de documento : documento electrónico Autores : Sergio Iván Hoyos Duque, Fecha de publicación : 2022 Títulos uniformes : Liver International Idioma : Inglés (eng) Palabras clave : delisting liver cancer outcomes radiological progression Resumen : Background & aim: Liver transplantation (LT) selection models for hepatocellular carcinoma (HCC) have not been proposed to predict waitlist dropout because of tumour progression. The aim of this study was to compare the alpha-foetoprotein (AFP) model and other pre-LT models in their prediction of HCC dropout. Methods: A multicentre cohort study was conducted in 20 Latin American transplant centres, including 994 listed patients for LT with HCC from 2012 to 2018. Longitudinal tumour characteristics, and patterns of progression were recorded at time of listing, after treatments and at last follow-up over the waitlist period. Competing risk regression models were performed, and model's discrimination was compared estimating Harrell's adapted c-statistics. Results: HCC dropout rate was significantly higher in patients beyond (24% [95% CI 16-28]) compared to those within Milan criteria (8% [95% IC 5%-12%]; p 2 (adjusted SHR of 3.17 [CI 2.13-4.71]), c-index of 0.71 (95% CI 0.65-0.77; p = .09 vs Milan). Similar discrimination power for HCC dropout was observed between the AFP score and the Metroticket 2.0 model. In patients within Milan, an AFP score >2 points discriminated two populations with a higher risk of HCC dropout (SHR 1.68 [95% CI 1.08-2.61]). Conclusions: Pre-transplant selection models similarly predicted HCC dropout. However, the AFP model can discriminate a higher risk of dropout among patients within Milan criteria. Mención de responsabilidad : Federico Piñero, Marcos Thompson, Ilka Boin, Aline Chagas, Emilio Quiñonez, Carla Bermúdez, Mario Vilatobá, Luisa Santos, Margarita Anders, Sergio Hoyos Duque, Agnaldo Soares Lima, Josemaría Menendez, Martín Padilla, Jaime Poniachik, Rodrigo Zapata, Martín Maraschio, Ricardo Chong Menéndez, Linda Muñoz, Diego Arufe, Rodrigo Figueroa, Simone R. Perales, Claudia Maccali, Rodrigo Vergara Sandoval, Lucas McCormack, Adriana Varón, Sebastián Marciano, Juan Mattera, Flair Carrilho, Marcelo Silva Referencia : Liver Int. 2022 Aug;42(8):1879-1890. DOI (Digital Object Identifier) : 10.1111/liv.15223 PMID : 35304813 En línea : https://onlinelibrary.wiley.com/doi/10.1111/liv.15223 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6091 Performance of pre-transplant criteria in prediction of hepatocellular carcinoma progression and waitlist dropout [documento electrónico] / Sergio Iván Hoyos Duque, . - 2022.
Obra : Liver International
Idioma : Inglés (eng)
Palabras clave : delisting liver cancer outcomes radiological progression Resumen : Background & aim: Liver transplantation (LT) selection models for hepatocellular carcinoma (HCC) have not been proposed to predict waitlist dropout because of tumour progression. The aim of this study was to compare the alpha-foetoprotein (AFP) model and other pre-LT models in their prediction of HCC dropout. Methods: A multicentre cohort study was conducted in 20 Latin American transplant centres, including 994 listed patients for LT with HCC from 2012 to 2018. Longitudinal tumour characteristics, and patterns of progression were recorded at time of listing, after treatments and at last follow-up over the waitlist period. Competing risk regression models were performed, and model's discrimination was compared estimating Harrell's adapted c-statistics. Results: HCC dropout rate was significantly higher in patients beyond (24% [95% CI 16-28]) compared to those within Milan criteria (8% [95% IC 5%-12%]; p 2 (adjusted SHR of 3.17 [CI 2.13-4.71]), c-index of 0.71 (95% CI 0.65-0.77; p = .09 vs Milan). Similar discrimination power for HCC dropout was observed between the AFP score and the Metroticket 2.0 model. In patients within Milan, an AFP score >2 points discriminated two populations with a higher risk of HCC dropout (SHR 1.68 [95% CI 1.08-2.61]). Conclusions: Pre-transplant selection models similarly predicted HCC dropout. However, the AFP model can discriminate a higher risk of dropout among patients within Milan criteria. Mención de responsabilidad : Federico Piñero, Marcos Thompson, Ilka Boin, Aline Chagas, Emilio Quiñonez, Carla Bermúdez, Mario Vilatobá, Luisa Santos, Margarita Anders, Sergio Hoyos Duque, Agnaldo Soares Lima, Josemaría Menendez, Martín Padilla, Jaime Poniachik, Rodrigo Zapata, Martín Maraschio, Ricardo Chong Menéndez, Linda Muñoz, Diego Arufe, Rodrigo Figueroa, Simone R. Perales, Claudia Maccali, Rodrigo Vergara Sandoval, Lucas McCormack, Adriana Varón, Sebastián Marciano, Juan Mattera, Flair Carrilho, Marcelo Silva Referencia : Liver Int. 2022 Aug;42(8):1879-1890. DOI (Digital Object Identifier) : 10.1111/liv.15223 PMID : 35304813 En línea : https://onlinelibrary.wiley.com/doi/10.1111/liv.15223 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6091 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001938 AC-2022-099 Archivo digital Producción Científica Artículos científicos Disponible Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9–50 years: a randomised, controlled, phase 2, non-inferiority study / Isabel Cristina Ramírez Sánchez
Título : Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9–50 years: a randomised, controlled, phase 2, non-inferiority study Tipo de documento : documento electrónico Autores : Isabel Cristina Ramírez Sánchez, Fecha de publicación : 2022 Títulos uniformes : The Lancet Infectious Diseases Idioma : Inglés (eng) Resumen : Background: Dengue is endemic in many countries throughout the tropics and subtropics, and the disease causes substantial morbidity and health-care burdens in these regions. We previously compared antibody responses after one-dose, two-dose, or three-dose primary regimens with the only approved dengue vaccine CYD-TDV (Dengvaxia; Sanofi Pasteur, Lyon, France) in individuals aged 9 years and older with previous dengue exposure. In this study, we assessed the need for a CYD-TDV booster after these primary vaccination regimens. Methods: In this randomised, controlled, phase 2, non-inferiority study, healthy individuals aged 9–50 years recruited from three sites in Colombia and three sites in the Philippines (excluding those with the usual contraindications to vaccinations) were randomly assigned 1:1:1 via a permuted block method with stratification by site and by age group using an independent voice response system to receive, at 6-month intervals, three doses of CYD-TDV (three-dose group), one dose of placebo followed by two doses of CYD-TDV (two-dose group), or two doses of placebo followed by one dose of CYD-TDV (one-dose group). Participants were also randomly assigned (1:1) to receive a CYD-TDV booster at 1 year or 2 years after the last primary dose. Each CYD-TDV dose was 0·5 mL and administered subcutaneously in the deltoid region of the upper arm. The investigators and sponsor, study staff interacting with the investigators, and participants and their parents or legally acceptable representatives were masked to group assignment. Neutralising antibodies were measured by 50% plaque reduction neutralisation testing, and geometric mean titres (GMTs) were calculated. Due to a change in study protocol, only participants who were dengue seropositive at baseline in the Colombian cohort received a booster vaccination. The primary outcome was to show non-inferiority of the booster dose administered at 1 year or 2 years after the two-dose and three-dose primary regimens; non-inferiority was shown if the lower limit of the two-sided adjusted 95% CI of the between-group (day 28 post-booster dose GMT from the three-dose or two-dose group vs day 28 GMT post-dose three of the three-dose primary regimen [three-dose group]) geometric mean ratio (GMR) was higher than 0·5 for each serotype. Non-inferiority of the 1-year or 2-year booster was shown if all four serotypes achieved non-inferiority. Safety was assessed among all participants who received the booster. This trial is registered with ClinicalTrials.gov, NCT02628444, and is closed to accrual. Findings: Between May 2 and Sept 16, 2016, we recruited and enrolled 1050 individuals who received either vaccine or placebo. Of the 350, 348, and 352 individuals randomly assigned to three-dose, two-dose, and one-dose groups, respectively, 108, 115, and 115 from the Colombian cohort were dengue seropositive at baseline and received a booster; 55 and 53 in the three-dose group received a booster after 1 year and 2 years, respectively, as did 59 and 56 in the two-dose group, and 62 and 53 in the one-dose group. After the three-dose primary schedule, non-inferiority was shown for serotypes 2 (GMR 0·746; 95% CI 0·550–1·010) and 3 (1·040; 0·686–1·570) but not serotypes 1 (0·567; 0·399–0·805) and 4 (0·647; 0·434–0·963) for the 1-year booster, and again for serotypes 2 (0·871; 0·673–1·130) and 3 (1·150; 0·887–1·490) but not serotypes 1 (0·688; 0·479–0·989) and 4 (0·655; 0·471–0·911) for the 2-year booster. Similarly, after the two-dose primary schedule, non-inferiority was shown for serotypes 2 (0·809; 0·505–1·300) and 3 (1·19; 0·732–1·940) but not serotypes 1 (0·627; 0·342–1·150) and 4 (0·499; 0·331–0·754) for the 1-year booster, and for serotype 3 (0·911; 0·573–1·450) but not serotypes 1 (0·889; 0·462–1·710), 2 (0·677; 0·402–1·140), and 4 (0·702; 0·447–1·100) for the 2-year booster. Thus, non-inferiority of the 1-year or 2-year booster was not shown after the three-dose or two-dose primary vaccination regimen in dengue-seropositive participants. No safety concerns occurred with the 1-year or 2-year CYD-TDV booster. Interpretation: CYD-TDV booster 1 year or 2 years after the two-dose or three-dose primary vaccination regimen does not elicit a consistent, meaningful booster effect against all dengue serotypes in participants who are seropositive for dengue at baseline. Mención de responsabilidad : Diana Leticia Coronel-Martinez, Juliana Park, Eduardo López-Medina, María Rosario Capeding, Andrés Angelo Cadena Bonfanti, María Cecilia Montalbán, Isabel Ramírez, María Liza Antoinette Gonzales, Betzana Zambrano, Gustavo Dayan, Zhenghong Chen, Hao Wang, Matthew Bonaparte, Andrey Rojas, Jenny Carolina Ramírez, Mae Ann Verdan, Fernando Noriega Referencia : Lancet Infect Dis. 2022 Jun;22(6):901-911. DOI (Digital Object Identifier) : 10.1016/S1473-3099(21)00706-4 PMID : 35364022 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1473309921007064 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6018 Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9–50 years: a randomised, controlled, phase 2, non-inferiority study [documento electrónico] / Isabel Cristina Ramírez Sánchez, . - 2022.
Obra : The Lancet Infectious Diseases
Idioma : Inglés (eng)
Resumen : Background: Dengue is endemic in many countries throughout the tropics and subtropics, and the disease causes substantial morbidity and health-care burdens in these regions. We previously compared antibody responses after one-dose, two-dose, or three-dose primary regimens with the only approved dengue vaccine CYD-TDV (Dengvaxia; Sanofi Pasteur, Lyon, France) in individuals aged 9 years and older with previous dengue exposure. In this study, we assessed the need for a CYD-TDV booster after these primary vaccination regimens. Methods: In this randomised, controlled, phase 2, non-inferiority study, healthy individuals aged 9–50 years recruited from three sites in Colombia and three sites in the Philippines (excluding those with the usual contraindications to vaccinations) were randomly assigned 1:1:1 via a permuted block method with stratification by site and by age group using an independent voice response system to receive, at 6-month intervals, three doses of CYD-TDV (three-dose group), one dose of placebo followed by two doses of CYD-TDV (two-dose group), or two doses of placebo followed by one dose of CYD-TDV (one-dose group). Participants were also randomly assigned (1:1) to receive a CYD-TDV booster at 1 year or 2 years after the last primary dose. Each CYD-TDV dose was 0·5 mL and administered subcutaneously in the deltoid region of the upper arm. The investigators and sponsor, study staff interacting with the investigators, and participants and their parents or legally acceptable representatives were masked to group assignment. Neutralising antibodies were measured by 50% plaque reduction neutralisation testing, and geometric mean titres (GMTs) were calculated. Due to a change in study protocol, only participants who were dengue seropositive at baseline in the Colombian cohort received a booster vaccination. The primary outcome was to show non-inferiority of the booster dose administered at 1 year or 2 years after the two-dose and three-dose primary regimens; non-inferiority was shown if the lower limit of the two-sided adjusted 95% CI of the between-group (day 28 post-booster dose GMT from the three-dose or two-dose group vs day 28 GMT post-dose three of the three-dose primary regimen [three-dose group]) geometric mean ratio (GMR) was higher than 0·5 for each serotype. Non-inferiority of the 1-year or 2-year booster was shown if all four serotypes achieved non-inferiority. Safety was assessed among all participants who received the booster. This trial is registered with ClinicalTrials.gov, NCT02628444, and is closed to accrual. Findings: Between May 2 and Sept 16, 2016, we recruited and enrolled 1050 individuals who received either vaccine or placebo. Of the 350, 348, and 352 individuals randomly assigned to three-dose, two-dose, and one-dose groups, respectively, 108, 115, and 115 from the Colombian cohort were dengue seropositive at baseline and received a booster; 55 and 53 in the three-dose group received a booster after 1 year and 2 years, respectively, as did 59 and 56 in the two-dose group, and 62 and 53 in the one-dose group. After the three-dose primary schedule, non-inferiority was shown for serotypes 2 (GMR 0·746; 95% CI 0·550–1·010) and 3 (1·040; 0·686–1·570) but not serotypes 1 (0·567; 0·399–0·805) and 4 (0·647; 0·434–0·963) for the 1-year booster, and again for serotypes 2 (0·871; 0·673–1·130) and 3 (1·150; 0·887–1·490) but not serotypes 1 (0·688; 0·479–0·989) and 4 (0·655; 0·471–0·911) for the 2-year booster. Similarly, after the two-dose primary schedule, non-inferiority was shown for serotypes 2 (0·809; 0·505–1·300) and 3 (1·19; 0·732–1·940) but not serotypes 1 (0·627; 0·342–1·150) and 4 (0·499; 0·331–0·754) for the 1-year booster, and for serotype 3 (0·911; 0·573–1·450) but not serotypes 1 (0·889; 0·462–1·710), 2 (0·677; 0·402–1·140), and 4 (0·702; 0·447–1·100) for the 2-year booster. Thus, non-inferiority of the 1-year or 2-year booster was not shown after the three-dose or two-dose primary vaccination regimen in dengue-seropositive participants. No safety concerns occurred with the 1-year or 2-year CYD-TDV booster. Interpretation: CYD-TDV booster 1 year or 2 years after the two-dose or three-dose primary vaccination regimen does not elicit a consistent, meaningful booster effect against all dengue serotypes in participants who are seropositive for dengue at baseline. Mención de responsabilidad : Diana Leticia Coronel-Martinez, Juliana Park, Eduardo López-Medina, María Rosario Capeding, Andrés Angelo Cadena Bonfanti, María Cecilia Montalbán, Isabel Ramírez, María Liza Antoinette Gonzales, Betzana Zambrano, Gustavo Dayan, Zhenghong Chen, Hao Wang, Matthew Bonaparte, Andrey Rojas, Jenny Carolina Ramírez, Mae Ann Verdan, Fernando Noriega Referencia : Lancet Infect Dis. 2022 Jun;22(6):901-911. DOI (Digital Object Identifier) : 10.1016/S1473-3099(21)00706-4 PMID : 35364022 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1473309921007064 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6018 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001856 AC-2022-024 Archivo digital Producción Científica Artículos científicos Disponible